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ABSTRACT OF DISSERTATION

DEVELOPMENT AND PRECLINICAL EVALUATION OF LONG-LASTING
COCAINE HYDROLASES FOR COCAINE OVERDOSE AND COCAINE USE
DISORDER TREATMENT
Cocaine is a plant-based illicit drug commonly involved in substance use disorder.
Although cocaine overdose and cocaine use disorders cause adverse health consequences
to individuals and the economic burden on their family and society, there are no FDA (Food
and Drug Administration) approved medications for treatment. Recently, it has been
recognized that delivery of cocaine hydrolase (CocH) is a promising therapeutic strategy.
Human butyrylcholinesterase (hBChE), the primary enzyme involved in cocaine
metabolism in human, have advantages over other candidates for the development of CocH.
Previous studies in our laboratory have designed and characterized hBChE mutants that
have ~4,000-fold improved catalytic efficiency against naturally occurring (-)-cocaine as
compared to the wild-type hBChE. Besides the catalytic efficiency, the biological half-life
is another essential factor that influences the desired therapeutic value in the long-term
treatment of cocaine use disorder. In order to provide prolonged effects to reduce
administration frequency in clinical use, efforts have been made to increase the retention
time of CocHs in blood circulation by fusing CocHs with other thermostable proteins or
their mutants, including human serum albumin (Albu) or the Fc region of the human IgG
(Fc).
In this dissertation, we demonstrated the clinical potential and the benefits of longlasting CocHs for cocaine overdose treatment. We used rodent models to show the ability
of AlbuCocH1 to block or reverse manifestations of toxic effects of cocaine. In addition, a
concomitant LC-MS/MS-based analysis was conducted to investigate the pharmacokinetic
profile of a lethal dose of cocaine with the presence of AlbuCocH1. These experimental
data demonstrated AlbuCocH1 as an effective cocaine detoxification agent by accelerating
the metabolism of cocaine.
In order to examine the potential therapeutic value of Fc-fused CocHs in the
treatment of cocaine use disorder, we conducted a series of behavioral experiments in rats
to evaluate the effectiveness and duration of Fc-fused CocHs in blocking or attenuating
cocaine-induced psychostimulant and discriminative stimulus effects. In addition, the

intravenous self-administration model was used to investigate the long-term effectiveness
of Fc-fused CocHs in blocking or attenuating the reinforcing effects of cocaine. It has been
shown that a single dose of E30-6-Fc (3 mg/kg) was able to effectively alter the cocaine
dose-response curve and attenuate the reinforcing efficacy of cocaine for at least a month
in both male and female rats.
In summary, AlbuCocH1 (TV-1380), which failed to meet the primary efficacy
endpoint in clinical trials for facilitating abstinence in cocaine-dependent subjects with a
weekly dosing schedule (due to the short biological half-life), is more suitable to be
developed as a cocaine detoxification agent. On the contrary, the newly designed Fc-fused
CocH (e.g. CocH3-Fc, E30-6-Fc) with higher catalytic efficiency and longer biological
half-life will be beneficial for long-term abstinence management in cocaine-dependent
individuals.

KEYWORDS: Therapeutic protein, Butyrylcholinesterase, Enzyme therapy, Substance use
disorder, Animal models of addiction, Cocaine self-administration
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1.
1.1.

Chapter One: Introduction

Cocaine
Cocaine is a natural alkaloid abstracted from the leaves of the Erythoxylum coca

plant (E. coca), a bush that grows in the mountain region of Latin America. Cocaine is a
powerful psychostimulant and highly addictive drug. Once consumed by humans, cocaine
interacts with multiple crucial proteins, especially monoamine reuptake transporters, to
induce a series of physiological and psychotic effects, which would eventually lead to
intoxication and chronic abuse disorder. Cocaine abuse is a worldwide social and public
health problem. However, there are no FDA approved medications for the treatment so far.
In this chapter, the pharmacokinetic and pharmacodynamics properties of cocaine,
the acute and chronic toxicity associated with cocaine use, and the medications under
development for cocaine overdose and cocaine use disorder treatment will be reviewed.
1.1.1. History of cultural use and medical use
The coca leaf has been used, chewed and sucked, for over a millennium since
ancient Indian discovered its origin and superpower. Initially, chewing of coca had been
reserved for the noble class and was usually associated with religious activity. Later, its
use became more widespread. Indians used it as a food substitute to overcome hunger, a
tool to stay warm, and a medicine to treat disease by shaman. In 16th century, when the
Spanish conquered the Incas, coca use was banned initially. However, Spaniards soon
found coca kept their Indian slaves worked harder in the mines. They abolished the ban
and began systematic cultivation of the plant (1). Coca was not able to become popular in
the Europe at that time, since its effects in the dried leaves decayed over long-term ocean
voyage, as well as the coca plant was difficult to grow in the European climate (2).
Cocaine, the major chemical constituent of the coca leaf, was isolated in the 1850s
by the efforts of German chemists - Friedrich Gaedcke and Albert Niemann. Over the next
1

two to three decades, people believed cocaine had powerful positive effects. Sigmund
Freud, a Viennese neurologist and the founder of psychoanalysis, was no doubt an
enthusiastic supporter of cocaine. In 1884, he published a medical analysis of cocaine –
“Uber Coca” (3). He identified cocaine as a central nervous system stimulant and an agent
that leads to euphoria, using himself as subject. He also advocated the therapeutic value of
cocaine, including in the treatment of morphine addiction. However, a number of other
adverse consequences were observed soon. Karl Koller, an ophthalmologist, explored
cocaine as a local anesthetic in eye surgery (3). This led to the only pharmaceutical use of
cocaine remaining to today.
At the same time, cocaine was also popular in the United States. It has been added
as an ingredient in Coca Cola and many patent medicines. Physicians prescribed coca and
cocaine products for a variety of illnesses. It was not until the early 20th century that people
realized the disastrous effects of cocaine. In 1914, 46 out of 48 states had laws restricting
the distribution or sale of coca and cocaine. Currently, cocaine is listed as Schedule II as a
drug with an acceptable medical use, but with a high potential for abuse as well (4). A 4%
cocaine chloride topical solution is indicated for the induction of local anesthesia of the
mucous membranes when performing diagnostic procedures and surgeries on or through
the nasal cavities in adults (5).

2

Figure 1-1. Timeline of major discoveries and policy changes related to cocaine.

3

1.1.2. Mechanism of action
Cocaine exerts its major physiological functions through inhibition of monoamine
reuptake transporters, including dopamine reuptake transporter (DAT), serotonin reuptake
transporter (SERT), and norepinephrine reuptake transporter (NET). Reuptake transporters
are essential membrane proteins to recycle and maintain a low extracellular concentration
of the neurotransmitters in the nervous system. By blocking reuptake transporters, cocaine
causes accumulation of neurotransmitters in the synaptic cleft, resulting in prolonged
activation of postsynaptic receptors. In vivo studies have shown that cocaine has inhibition
constants (Ki values) of 0.14, 0.64, and 1.6 M at the SERT, DAT, and NET, respectively
(6).
Cocaine also binds to two classes of neurotransmitter receptors, including
muscarinic acetylcholine receptors (mAChRs) and sigma receptors. In rats, cocaine inhibits
mAChRs in heart and brain with a higher affinity at M2 receptors than at M1 receptors (7).
In addition, evidence shows that cocaine also binds to human mAChRs (8). Sigma
receptors are expressed in numerous regions in the brain and suggested to contribute to the
delusions and psychoses induced by certain drugs (9). It has been found that cocaine binds
to sigma receptors with a Ki value (6.7 ± 0.3 µM) compatible with a blood concentration
reported to produce psychosis in human volunteers (10). It has also been proposed that the
psychotomimetic effects of cocaine may be partially due to its interaction with sigma
receptors (10).
In addition, cocaine binds to several voltage-gated ion channels, which contributes
to its local anesthetic effects. Although there are voltage gated ion channels in nerve and
cardiac tissue, this interaction is more likely to play a role in the cardiotoxicity of cocaine
rather than its effects in the CNS (11). Ex vivo studies, using isolated cardiac myocytes,
have shown that cocaine decreased the inward sodium current by binding with inactivated
state of sodium channels (12), decreased the outward potassium current by binding to
cardiac potassium rectifier channels (13), and increased the probability and duration of Ltype calcium channel opening (14).

4

1.1.3. Pharmacokinetics of cocaine
There are basically two chemical forms of cocaine: base (“crack”) or salt (“cocaine
hydrochloride”). They contain the same cocaine molecule but differ in physical properties.
Cocaine base is insoluble in water but melts at 98C, which allows to be smoked (SM).
Cocaine salt is highly water soluble, which is readily for intravenous injection (IV) or
insufflation (INS) snorting (15).
1.1.3.1.

Absorption and distribution

Cocaine is absorbed through the mucous membranes of the nose and mouth, and
respiratory tracts. Due to the first-pass metabolism, the bioavailability of cocaine after oral
intake (PO) is only 30-50% in human (16). The bioavailability of cocaine is higher when
administered via other routes with approximately 90% with SM and 80% with INS (17).
The administration route of cocaine has an impact on the onset of its action as well. IV and
SM produce effects almost instantly (within 1 min), whereas INS or PO result in slower
onset of 5 min or up to 30 min, respectively (17).
Cocaine (pKa = 8.6) is mainly staying its ionized form in the physiological PH (7.4).
It distributes to most body organs, including the heart, kidney, adrenals, and liver. Most
importantly, the high solubility of cocaine in lipids ensures that it crosses the blood brain
barrier (BBB) to reach the central nervous system (18). PET study indicates that the peak
concentration of cocaine in basal ganglia after administration of 40 mg cocaine was about
10 M, which is more than 10-fold higher than peak concentration in the plasma (18, 19) .
1.1.3.2.

Metabolism

Since cocaine is a diester of the base of ecognine, the major cocaine metabolism
pathway is enzymatic hydrolysis at either benzoyl ester or methyl ester by the action of
blood and liver esterases. The metabolic pathways and major metabolites are displayed in
Figure 1-2. In human, butylcholinesterase (BChE) and liver carboxylesterase 2 (hCE-2)
catalyze cocaine hydrolysis at the benzoyl ester group (20), producing benzoic acid and
ecgonine methyl ester (EME).

Liver carboxylesterase 1 (hCE1) catalyzes cocaine

hydrolysis at methyl ester, producing benzoylecognine (BE) (21). BE and EME are the
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major metabolites of cocaine under physiological condition in human. Both of them lack
the psychoactive effects of cocaine. They are not expected to cross BBB (22) and are
inactive at dopamine transporter (23).
In addition, a small portion of cocaine undergoes N-demethylation by hepatic P450
to produce norcocaine, which is an active metabolite of cocaine. Norcocaine binds to
dopamine reuptake transporter (23) and can readily enter the primate brain (22). However,
PET study with carbon-11 labeled cocaine revealed that norcocaine does not contribute to
the subjective effect experienced immediately after IV administration of pharmacological
active dose of cocaine (22, 24). The formation of norcocaine attributes to the hepatotoxicity
of cocaine (25).
In human, the plasma clearance half-life (T1/2) of cocaine is dose dependent (1 - 3
mg/kg, IV), ranging from 40 min to 90 min (26). The same study has found that the initial
plasma concentration of cocaine after 1 mg/kg IV administration is around 550 ng/ml (~
1.81 M). In rats, the T1/2 of cocaine is relatively shorter. The T1/2 of cocaine is overall
close to 13.0  1.5 min with the dose range from 0.5 mg/kg to 3 mg/kg (IV) (27). The same
study has found that the initial plasma concentration of cocaine after 1 mg/kg IV
administration is 755  119 ng/ml (2.49  0.39 M).
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Figure 1-2. Metabolism pathways and major metabolites of cocaine (28).
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1.1.3.3.

Excretion

Studies showed that only ~1% of the cocaine dose might be excreted unchanged in
urine. The majority urinary metabolites are BZE (25-40%) and EME (15-25%) (29).
According to literature, up to 65% of the dose is recoverable in urine by 3 days after cocaine
use. Therefore, urine is a good specimen to monitor prior cocaine exposure.
1.2.

Cocaine intoxication

1.2.1. Toxicity of cocaine
The major toxic effects associated with acute and chronic use of cocaine are
neurotoxicity and cardiovascular toxicity. The major mechanisms underlying these toxic
effects are reviewed below.
1.2.1.1.

Neurotoxicity

Cocaine abusers present a serial of neurological and cognitive impairments,
including deficits in cognition, loss of control, impulsiveness, etc. In addition, cocaine
addicts often suffer from neurological complications, like seizures, cerebral ischemia,
cerebral hemorrhages and cerebral atrophy (30). The mechanism of neurotoxicity induced
by acute and chronic use of cocaine is complex and involves various cellular and molecular
pathways. The major reasons leading to neuronal death includes oxidative stress,
excitotoxicity, and apoptosis.
1.2.1.1.1. Oxidative stress
Oxidative stress describes the unbalance between the production of reactive oxygen
and nitrogen species (ROS and RNS) and the response of physiological antioxidant
mechanisms. Oxidative stress plays an important role in the toxic effects of various abuse
drugs, including cocaine. Cocaine use leads to dysregulation of brain dopaminergic system,
resulting in increased extracellular DA concentration. Excessive concentration of DA could
be neurotoxic due to the formation ROS (e.g. H2O2, O2-, OH, and NO3-) during its
metabolism through auto-oxidation or monoamine oxidase (MAO) action (30). It has been
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shown that cocaine exposure led to an increase in H2O2 level in the prefrontal cortex (PFC)
and striatum of rats (31). On the other hand, studies demonstrated that cocaine exposure
induced changes in activity of major antioxidant enzymes, including catalase, glutathione
peroxidase, and superoxide dismutase in the cortex and striatum of animals (32). The levels
of antioxidants, like glutathione and reduced vitamin E (33), were also reported to be
downregulated upon exposure to cocaine. If the antioxidant system is not able to deal with
the increased level of ROS, cell death will occur in dopaminergic cells and surrounding
cells due to oxidation of important cellular macromolecules such as amino acids,
phospholipids, and nucleic acids (34).
1.2.1.1.2. Excitotoxicity
Excitotoxicity means cell death caused by toxic effects of excitatory
neurotransmitters. Cocaine use results in an increase of extracellular glutamate
concentration in several brain regions, like the ventral tegmental area (VTA), nucleus
accumbens (NAc), PFC, and striatum (35). Glutamate triggers the activation of NMDA
receptors, resulting in an increases in intracellular Ca2+ concentrations. These increases
lead to activation of Ca2+ dependent enzyme that causes degradation of proteins,
phospholipids, and nucleic acids, eventually, resulting in neuronal death (36).
1.2.1.1.3. Apoptosis
It has been demonstrated that the abused substances, including cocaine, could
induce neuronal cell death by apoptosis. There are evidences indicating that the cocaineinduced apoptosis may be mediated by oxidative stress (37) or mitochondrial dysfunction.
In vivo studies have shown that cocaine could cause biochemical features of apoptosis, like
activation of caspases, loss of mitochondrial potential, and cytochrome C release (38).
1.2.1.2.

Cardiovascular toxicity

Cardiac toxicity is the most frequent complication of cocaine use. A large number
of cardiovascular diseases have been associated with acute or chronic cocaine use,
including hypertension, acute myocardial ischemia and infarction, cardiac dysrhythmias
and endocarditis, and so on (39, 40). A large percentage of sudden deaths associated with
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cocaine use are from cardiac causes. The toxic effects of cocaine on the heart and vascular
system are attributed to two major pharmacological properties of cocaine.
1.2.1.2.1. Sympathomimetic effects
The primary pharmacological property of cocaine is to block the reuptake of
catecholamines. The accumulation of catecholamines leads to sympathomimetic
stimulation not only of the central nervous system (CNS) but also of the heart muscle and
the vascular smooth muscle (41). The increased norepinephrine levels in vascular smooth
muscle stimulates -adrenergic receptors, resulting in a vasoconstrictor response (41).
Experiments using preparations without sympathetic innervation show that cocaine may
be able to induce vasoconstriction via directly increasing calcium flux into smooth muscle
cells (42). Vasoconstriction eventually leads to an increase in blood pressure and coronary
vascular resistance. On the other hand, accumulation of catecholamines in the myocardium
stimulate the -adrenergic receptors, resulting in an increase in heart rate, an increase in
cardiac automaticity, and possibly other tachyarrhythmias (41). Potentiation of adrenergic receptors also causes increases in cAMP level and activation of cAMPdependent protein kinase, resulting in increases in calcium levels in the myocardial cells
(43). Activation of -adrenergic receptors in the heart by cocaine may also contribute to
higher calcium levels within myocardium (43).
1.2.1.2.2. Local anesthetic effects
As mentioned above, cocaine also binds to and blocks several kinds of ion channels.
Evidence shows that cocaine blocks the fast sodium channel in the myocardium, resulting
in a depression of depolarization and slowing of conduction velocity. This effect leads to
an abnormal ECG profile similar to that caused by other type I antiarrhythmic agents (44).
This local anesthetic and membrane-stabilizing property is responsible for a negative
inotropic effect of cocaine (41).
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1.2.2. Prevalence of cocaine overdose
Cocaine remains among the most common illicit drug associated with visits to
United States hospital emergency departments (ED). Based on data from the Substance
Abuse and Mental Health Service Administration (SAMHSA) (45), during 2011,
approximate half of drug misuse or abuse ED visits involved illicit drugs (1.25 million out
of 2.5 million). Although the majority (56.3%) of illicit drug ED visits involved multiple
drugs, cocaine is one of the most commonly involved drugs, with 505,224 ED visits
(40.3%).
According to the information collected by National Center for Health Statistics
(NCHS) at the Center for Disease Control and Prevention (46), among the more than
64,000 drug overdose deaths estimated in 2016, more than 10,000 overdose deaths
involved cocaine. From the lowest number in 2010 to 2015, there’s been a 1.6-fold increase
in the total number of deaths involving cocaine (47).
1.2.3. Current interventions used in the emergence departments
The first step management of cocaine overdose in the ED includes physical cooling
since the toxic effects of cocaine are able to raise core temperature and lead to lifethreatening hyperthermia (48). Medications commonly used following cooling aim to
reduce the effects of cocaine in the CNS and cardiovascular system (49). All of the
treatments are only able to reduce/reverse the symptoms caused by cocaine while cocaine
still existing in the patient’s body.
1.2.3.1.

Benzodiazepines and other GABA-active agents

Benzodiazepine receptor agonists such as lorazepam, diazepam, and midazolam
and gamma-aminobutyric acid (GABA) reuptake inhibitors, such as tiagabine, are
commonly used in the EDs to enhance the inhibitory effects of GABA (49). This type of
medication leads to sedation and centrally mediated decrease in sympathetic activity. The
potential adverse effects include over-sedation and respiratory depression associated with
large and repeated doses (50).
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1.2.3.2.

Calcium channel blocker

Several classes of calcium channel blockers, including dihydropyridine,
phenylalkylamine, and benzothiazepine, have been used to reverse cocaine-induced
increases in systemic vascular resistance and arterial pressure, as well as frequency of
coronary vasospasm (49). Potential adverse effects are greatest with the dihydropyridine
agents such as isradipine, nifedipine, nimodipine, and amlodipine since their actions on
vasodilation and hypotension can lead to reflex tachycardia (51).
1.2.3.3.

Nitric oxide-mediated vasodilators

Nitric-oxide mediated vasodilators, such as nitroglycerin and nitroprusside, are also
important agents in treatment of cocaine-associated hypertension, coronary artery
vasospasm, and chest pain (49). However, these agents may cause hypotension.
1.2.3.4.

Beta-adrenergic receptor and beta/alpha- adrenergic receptor antagonists

Non-selective 1/2 antagonist, like phentolamine, is recommended as an initial
treatment for persistent hypertension form cocaine (52). Due to the hyperadrenergic
symptoms associated with cocaine, non-selective 1/2 antagonist, like propanol, are
commonly considered to resolve this situation (49). In 1985, a phenomenon of “unopposed
-stimulation” was reported, showing selective blocking of  receptors may cause a
paradoxical hypertension in cocaine-positive patient (53). However, reports on large
number of patients treated with  antagonist after cocaine exposure generally showed
neutral or beneficial effects on cardiovascular outcomes (40). Mixed 1/2/1 antagonist,
like carvedilol and labetalol, also showed beneficial results in studies on their effects on
cardiovascular symptoms caused by cocaine (49).
1.3.

Cocaine use disorder
In the DSM-5(54), psychiatric diagnoses of cocaine abuse and cocaine dependence

are replaced by one diagnosis – cocaine use disorder (CUD). Cocaine dependence is
approximately comparable to a moderate to severe subtype of CUD, whereas, cocaine
abuse is equivalent to the mild subtype.
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1.3.1. Diagnosis and epidemiology
According to the World Drug Report 2017 (55), cocaine use in terms of annual
prevalence has remained stable in recent years on a global level, at around 0.4 percent of
population aged 15-64 years. It is estimated that there are nearly 17 million past-year user
of cocaine worldwide, with high annual prevalence rates in North America (1.8%), Oceania
(1.5%), Western and Central Europe (1.1%). The largest number of cocaine user worldwide
was found in North America (33% of the global total), followed by Western and Central
Europe (20%) and South America, together with the Caribbean and Central America (17%)
(55).
Cocaine use disorder is diagnosed when someone experiences clinically significant
impairment caused by the recurrent use of cocaine, including health problems, physical
withdrawal, persistent or increasing use, and failure to meet major responsibilities at work,
school, or home (15). According to the 2016 National Survey on Drug Use and Health
(NSDUH) (56), in 2016, the estimate of about 1.9 million people aged 12 or older who
were current users of cocaine included about 432,000 current users of crack. NSDUH
respondents who used cocaine or crack in the past 12 months were categorized as having a
cocaine use disorder if they met the DSM-IV criteria for either dependence or abuse for
cocaine. About 867,000 people aged 12 or older in 2016 had a cocaine use disorder in the
past year. This number of people represents 0.3 % of the population aged 12 or older. The
percentage of the population aged 12 or older with a cocaine use disorder remained stable
between 2010 and 2016. However, the percentage in 2016 was lower than the percentages
in 2002 to 2009.
1.3.2. Neurology of cocaine use disorder
Serials of reviews published by Dr. Koob and Dr. Volkow have demonstrated the
brain regions and neurocircuits involved in different stages of substance use disorders using
evidence from animal models and human imaging studies (57-60). Neuroadaptive changes
induced by chronic cocaine use in these brain circuits responsible for reward, memory and
learning, emotion, motivation, and executive function are underlying the transition from
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recreational use to compulsive cocaine use disorder (60). A better understanding of these
fundamental mechanisms shed light on the discovery and development of medicines for
cocaine use disorder.
1.3.2.1.1. Reward circuit – VTA and striatum
The initial reward (reinforcing) effect of cocaine is mediated by its action in the
mesolimbic dopamine pathway, which is composed of dopaminergic neurons located in
the ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc) in ventral
striatum. Most neurons (up to 95%) in the striatum are GABAergic medium spiny neurons
(MSN), typically segregated into those expressing D1 dopamine receptors (D1R) and those
expressing D2 dopamine receptors (D2R) (61). This circuit plays important roles in
processing the reward-related stimuli, including natural rewards (e.g. food and sex) and
drugs of abuse (62).
A human imaging study demonstrated that intoxicating doses of cocaine increase
the level of dopamine in the ventral striatum and this is associated with the subjective effect
of cocaine (60). This fast and steep increase in dopamine level mimics or even exceeds the
dopamine changes induced by the phasic dopamine cell firing (fast burst firing > 30 Hz)
associated with natural reward at the normal condition (63). Studies further showed that
the activation of low-affinity D1R by the DA increase from phasic firing is necessary to
produce the reinforcing (reward) effect (64), whereas, activation of D2R alone by DA
release from tonic firing is not sufficient (65).
It has been found in human imaging studies that the subjects with a history of drug
abuse have long-lasting decreases in the numbers of D2R compared with non-drug users
(66). Moreover, cocaine abusers show reduced DA release in response to intravenous
methylphenidate injection, indicating decreased DA activity (67). These changes are
proposed to be reasons for anhedonia reported by addicted individuals (60).
Animal studies enable us to learn the adaptive changes in a more detailed level. It
has been shown that one exposure to cocaine induced long-term potentiation (LTP) of
AMPA-mediated currents at excitatory synapses onto dopamine cells in the VTA for at
least 5 days (68). Later, it was found that self-administration of cocaine, but not passive
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cocaine infusions, produced a persistent potentiation of VTA excitatory synapses, which
was resistant to behavioral extinction and was present after 3 months abstinence (69).
Using whole-cell synaptic physiology in NAc brain slices, Kourrich et al. demonstrated a
progression of bidirectional changes in glutamatergic synaptic strength after repeated in
vivo exposure to cocaine. NAc neurons from cocaine-experienced mice first developed a
robust potentiation of AMPA-mediated synaptic transmission during a protracted drug-free
period. A single re-exposure to cocaine during extended withdrawal became a potent
stimulus for synaptic depression, abruptly reversing the initial potentiation (70). Additional
evidence indicated dysregulated glutamate transmission in the NAc following chronic
cocaine exposure and during withdrawal (71, 72), an effect is hypothesized to lead to a
drive to engage in drug-seeking (73).
There is evidence demonstrating the gradual engagement of dorsal striatum along
the development of habitual and compulsive cocaine use (57). Microdialysis studies have
shown that prolonged cocaine-seeking increased dopamine release in the dorsal striatum
but not ventral striatum (74). In addition, disconnection of the ventral striatum from dorsal
striatum led to deficits in rats with compulsive intake but not in rats that recently acquired
cocaine self-administration under the second-order schedule (75).
Overall, based animal studies, the neuroadaptive changes in the mesolimbic
pathway begins with one administration of the drug, develops into LTP first in the VTA
then NAc, and via feedback loops subsequently engages the dorsal striatum (57).
1.3.2.1.2. Memory and learning – Hippocampus
The connection between addiction and learning/memory is based on the fact that
an environment, a person, or a cue associated with previous experience of cocaine use can
trigger an intense desire for cocaine and, thereafter, induce relapse (60). Declarative
memory, which is mediated by the hippocampus and related areas, is believed to be
involved in learning and linking the affective conditions or circumstances with drug-taking
experience (57). Human studies with PET and fMRI have revealed that regions linked with
memory are activated during acute cocaine intoxication (76), and cue-elicited cocaine
craving (77). In addition, animal studies demonstrated that excitotoxic lesion of ventral
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subiculum of the hippocampus caused moderately impaired acquisition of cocaine selfadministration in rats (78). There are also evidences indicating the involvement of a
dysregulated hippocampus in the transition to cocaine addiction. In one animal study, rats
allowed extended access, but not limited access, to cocaine showed impaired object
recognition, which is sensitive to hippocampal function (79).
1.3.2.1.3. Impulsivity and executive function – Prefrontal cortex
The prefrontal cortex (PFC), including anterior cingulate (ACC), orbitofrontal
cortex (OFC), and dorsolateral prefrontal cortex, plays important roles in executive
function and motivation driven behavior. It has projections into the motor and sensory
cortex as well as to subcortical areas including striatum and amygdala and VTA. It is
widely believed that the prefrontal cortical dysfunction is crucial to the addiction process
(80). As demonstrated in human studies and clinical observations, chronic drug users,
including cocaine addicts, always show augmented impulsivity, deficits in executive
function and impairment inhibitory control (57, 60).
Moreover, a large body of evidence implied that the malfunction of PFC plays an
important role in relapse. It has been found in human imaging studies that the OFC appears
to be hypoactive in the detoxified cocaine abuser (tested during withdrawal) (81) and this
is associated with the reductions in striatal D2R (82). In addition, activation of OFC has
been reported during intoxication in drug addicts, but not native subjects, and the level of
activation predicted the intensity of drug-induced craving (83). Based on this, it has been
hypothesized that drug or drug-associated cue reactivates OFC during withdrawal,
resulting in compulsive drug taking (60). Evidences from rodent studies also suggests that
drug and cue-induced reinstatements are mediated by glutamate projection that links the
PFC to the NAc (58, 84).
1.3.2.1.4. Emotion – Extended amygdala
One remarkable feature of cocaine addiction is the presence of emotional or
motivational withdrawal syndrome, including states of irritability, dysphoria and stress,
when the rewarding effects of cocaine wear off (85). This state is not only attributed to the
loss of function in the brain reward system, but also the activation of brain stress system in
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extended amygdala. It is a region composed of several basal forebrain structures, including
the bed nucleus of the stria terminalis (BNST), the central nucleus of the amygdala (CeA),
and a transition zone in the medial part of the nucleus accumbens (e.g., shell) (86).
Both the hypothalamic-pituitary-adrenal (HPA) axis and brain stress system
mediated by corticotropin-releasing factor (CRF) are dysregulated by the chronic
administration of cocaine (58). During withdrawal, elements of brain stress systems, such
as CRF, norepinephrine, dynorphin, hypocretin, and substance P are elevated, producing
aversive or stress-like states (87). Meanwhile, elements involved in brain anti-stress
systems, such as neuropeptide Y, nociception, and endocannabinoids, are downregulated
(87). It has been shown in a rodent self-administration model that CRF antagonists
selectively blocked the increased cocaine intake with extended access (88).
1.3.3. Preclinical models to evaluate medications for cocaine use disorder
Animal models are useful to study the physiological effects and abuse associated
properties of cocaine. They are also widely used to evaluate medications to treat cocaine
use disorder. Locomotor activity tests and drug discrimination tests are commonly used as
high throughput methods to screen candidate agents. Whereas, self-administration, as a
direct method measuring the reinforcing effects of cocaine, serves as a gold standard to
assess the potential therapeutic value of promising agents.
1.3.3.1.

Locomotor activity

Cocaine as a psychostimulant, when entering the brain, could cause increased
extracellular levels of monoamines by blocking monoamine reuptake transporters. One
remarkable physiological consequence in rodents is elevated psychomotor behaviors.
Moreover, repeated exposure to such psychostimulants leads to a progressive and enduring
enhancement in the motor stimulant effect elicited by a subsequent drug challenge, which
is called behavioral sensitization. This experiment has been proposed to model the druginduced plastic changes which underlie the transition to drug addiction (89). However,
assessment of cocaine-induced locomotor activity after cocaine self-administration training
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showed that extended access to cocaine fails to produce locomotor sensitization (90) but
does produce a sensitized stereotyped behavior response (91).
1.3.3.2.

Drug discrimination

Drug discrimination (DD) techniques have been widely used to classify and
characterize the interoceptive effects of abused drugs. It can be viewed as analogues to the
measurement of the subjective effects induced by drugs in humans (92). In this paradigm,
pressing one lever (e.g. left) is reinforced when the training drug is injected before the
session, while responding on the other lever (e.g. right) is reinforced when vehicle is
injected. During test session, lever choice reveals whether the rat perceives the test
compound as training drug-like or vehicle-like (92).
Based on the hypothesis that the ability to perceive and identify the particular
subjective effects of drugs and their withdrawal syndromes promotes drug-seeking
behaviors (93), it is believed that attenuation of such effects might serve as a useful
indicator of therapeutically beneficial actions during preclinical evaluation of candidate
medications for drug addiction treatment (94). Naltrexone, which is an FDA-approved
medication for management of opioid (and alcohol) abuse and addiction, has been well
characterized in preclinical drug discrimination studies and approved to be effective for
modulating the subjective effects of abused opioids (95, 96).
The discriminative stimulus effects of cocaine have been comprehensively studied.
It has been found that this effect of cocaine can be fully substituted by other indirectly
acting dopamine receptor agonists (e.g. methamphetamine, methylphenidate) (97),
partially substituted by dopamine D1R and D2R receptor agonists, and surmountably
antagonized by D1R and D2R blockers (97, 98).
1.3.3.3.

Self-administration

Drug intravenous self-administration (IVSA) in laboratory animals has repeatedly
proven to be a reliable model and direct measurement of the reinforcing effects of drugs
with substantial predictive validity. It has been widely used in preclinical evaluation of
pharmacotherapies for the treatment of drug abuse (99). Modifications of this model could
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be used to directly test the reinforcing properties of the drug and may be linked to different
symptoms associated with addiction as described in DSM-V.
1.3.3.3.1. Maintenance
Preclinical evaluation of anti-addiction treatment is based in part on the assumption
that an effective treatment medication should be able to make the abused drug more like
saline or a lower dose by antagonizing its reinforcing properties (99). However, cocaine
self-administration is featured by an inverted U-shaped dose-response curve relating unit
dose (dose per infusion) to number of infusions per session (or response rate) (100).
Reduced reinforcing effects may not be manifested as decrease in self-administration. The
results would be difficult to interpret, if only a single dose is tested. Therefore, it is always
important to assess the dose-response curve (DRC) under a fixed-ratio schedule. A shift
(e.g, right, left, up, down) in the DRC for a drug of abuse indicates change in the efficacy
of reinforcing effects of the drug.
1.3.3.3.2. Escalation
The transition from causal to compulsive drug consumption is critical to the
development of addiction. An extended access paradigm has been developed to model this
feature of drug addiction (101, 102). In this model, rats are trained to self-administer
cocaine initially on a FR1 schedule across daily one-hour sessions. After stable responding
is reached, they are assigned to two groups with differential cocaine access. Rats in long
access group (LgA) are allowed to self-administer cocaine daily in a six-hour session,
whereas rats in short access group (ShA) are maintained in one-hour sessions (101). The
LgA rats exhibit a gradual escalation in cocaine intake and the elevated intake usually
persists later when short-access is resumed.
1.3.3.3.3. Motivation
Progressive ratio (PR) schedules are been used to evaluate the reinforcing efficacy
of a drug (103), as well as the motivation to obtain drug by rats via self-administration. In
this model, the number of responses required to receive one infusion of drug is increased
progressively within the self-administration session until responses cease. A “breaking
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point” could be determined as the final ratio completed, which presumably reflects the
maximal effort that a rat will expend to get a drug infusion (103).
1.3.3.3.4. Reinstatement
The most difficult clinical problem in the treatment of human drug addiction is high
rates of relapse, which is defined as the resumption of drug use after a period of abstinence
(104, 105). Clinical and laboratory studies have demonstrated that, in addition to
withdrawal symptoms, exposure to the abused drug, stress, and drug-associated cue can
serve as triggers to induce relapse (106), in which re-exposure to abused drug itself is the
most powerful one in both human and animals. In 1981, de Wit and Stewart reported that
non-contingent priming injections of cocaine or re-exposure to cocaine-paired cues
reinstates lever-pressing behavior following extinction of drug-reinforced behavior (107).
Later, they proposed this reinstatement model could be used to study factors involved in
relapse to drug use (106). In the between-session procedure, training for drug selfadministration, the extinction of drug-reinforced behavior, and tests for reinstatement are
conducted during sequential daily sessions (106).
1.4.

Small molecules under development for cocaine use disorder
Most small-molecule drug candidates under development for cocaine use disorder

are aiming to modulate the disrupted neurochemistry caused by chronic cocaine use in
order to resemble those of healthy individuals (108). The primary targets for modulation
include dopaminergic pathway and other neurotransmitter systems involved in the
development and relapse of cocaine use disorder.
1.4.1. Dopaminergic system
The intuitive mechanism of a pharmacotherapy to treat cocaine use disorder is to
block cocaine’s action on the dopamine reuptake transporter (109). Naltrexone, the µopioid receptor antagonist, is one example of an antagonist medication approved for the
treatment of opioid-use disorder. However, as the cocaine binding site in its primary target
- dopamine reuptake transporter (DAT) - overlaps with dopamine’s (DA) binding site (110),
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it is difficult to directly block the action of cocaine without interrupting the essential
function of dopaminergic system. “Agonist therapy” is a pharmaceutical strategy that
works the opposite way. Candidate small molecules share the pharmacodynamics
mechanisms of action of cocaine, but usually have distinct pharmacokinetic characteristics,
like bioavailability associated administration route, slow onset of action, long duration of
action, to lower their abuse liability (109). Several FDA-approved medications for other
indications, which also act as either a dopamine releaser or dopamine reuptake inhibitor,
have been assessed in human laboratory studies and clinical trials for their efficacy to
attenuate the reinforcing effects of cocaine and to manage cocaine dependence, including
methylphenidate, d-amphetamine, bupropion and modafinal (108, 111). It was found that
dopamine releasers (e.g. d-amphetamine) are more effective than dopamine reuptake
inhibiters (e.g. methylphenidate) for reducing the use of cocaine (111). Bupropion was
demonstrated to be effective in facilitating cognitive behavioral therapy (CBT) (112),
although the effect was small.
Another potential therapeutic target in the dopaminergic system is dopamine D3
receptor (D3R) (113), which is a D2-like dopamine receptor with restricted localization to
the ventral striatum (114) and enhanced expression in the brains of cocaine-dependent
individuals (115, 116). During the latest decades, D3R-selective antagonists and partial
agonists with high affinity and varying efficacies have been discovered and assessed in
preclinical animal models of drug addiction, showing promising results in rodent models
of relapse-like behavior (117). However, to date, no D3R-selective or preferential
antagonists or partial agonists showed positive results in clinical trials for cocaine use
disorder.
1.4.2. GABAergic system
γ-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the CNS
and GABAergic neurons modulate the dopaminergic system through heavy innervation in
the VTA and NAc. It has been proposed that facilitating the function of GABA could
antagonist the action of cocaine in the brain. Several FDA approved GABA-A or GABAB agonists have been assessed in clinical trials for facilitating abstinence in cocaine21

dependent individuals. It has been found that topiramate, a GABA-A receptor agonist, can
apparently facilitate cognitive behavioral therapy to achieve better abstinence (118, 119).
However, baclofen, gabapentin and tiagabine generated mixed results in clinical trials
(108). More studies are required to determine their therapeutic efficacy.
1.4.3. Glutamatergic system
Glutamate is one of the primary excitatory neurotransmitters in the CNS and acts
on two families of glutamate receptors, including inotropic glutamate receptors (iGluR, e.g.
NMDA and AMPA) and metabotropic glutamate receptors (mGluR1-8). It has been
hypothesized that the imbalance of glutamate homeostasis underlies the impaired
communication between the PFC and NAc (120). There is growing preclinical evidence
suggesting that glutamatergic neurotransmission system is essentially involved in relapse
to drug-seeking behaviors (84).
One therapeutic strategy based on this knowledge is to normalize glutamate
homeostasis in order to reverse the neural maladaptive changes caused by chronic cocaine
exposure (120). N-acetyl-cysteine (NAC), a prodrug of cysteine, has been proposed to act
as anti-relapse agent and offer benefits for treating cocaine use disorder (121). NAC is
oxidized into cystine within the brain and drives the glial cystine-glutamate exchanger to
release glutamate and restore basal extracellular glutamate levels to normalize the
compromised cortocostraiatal function. Preclinical studies have demonstrated that the
NAC treatment could reduce cue and cocaine-primed drug seeking in formerly cocaine
dependent rats (122, 123). In the molecular level, NAC reversed the changes in spine
morphology and AMPA/NMDA ratio produced after withdrawal from self-administration
of cocaine (124). A proton magnetic resonance spectroscopy (1H MRS) study in in
cocaine-dependent patients and normal controls revealed that NAC normalizes glutamate
levels in cocaine-dependent patients (125). In 2013, a randomized, double blinded, placebo
controlled clinical study revealed NAC failed to show impact on cocaine abstinence (126).
However, in subgroup of the sample that was already abstinent, NAC with high dose (2400
mg/day) prolonged the time to relapse and reduced craving, indicating NAC may work as
a relapse-prevention agent rather than an abstinence-promoting agent (126).
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Among the eight subtypes of mGluRs, mGluR2/3 and mGluR5 are promising targets
for development of anti-addiction medications (120). It has been demonstrated using
experimental animals that both agonists (or positive allosteric modulators) of mGluR2/3
(127) and antagonists (or negative allosteric modulators) of mGluR5 (128, 129) are able to
reduce cocaine self-administration and reinstatement of drug-seeking. However, no agents
in this category have been studied in their effects in facilitating cocaine abstinence in
clinical trials so far.
1.4.4. Others
Medicines that modulate other neurochemical and neuroendocrine systems,
including the serotonin system (antidepressants), endocannabinoids system (CB1/2
receptor agonist), and neuropeptides involved in brain stress system (CRF1 antagonist),
have been proposed and tested in preclinical and clinical studies to treat cocaine use
disorder (130). However, none of them have been effective in clinical trials so far.
1.5.

Biologics under development for cocaine use disorder/overdose
As discussed above, the small molecule-based medications for cocaine use disorder

is aiming to alter the pharmacodynamics of cocaine by direct or indirect antagonizing
cocaine’s action or correcting the disrupted neurochemistry system. However, despite the
decades of effort, no candidate agent has been approved as an effective pharmacotherapy
for cocaine use disorder. Therefore, new approaches using a pharmacokinetic (PK) strategy
have been developed. These protein-based methods use either enzyme or antibody/vaccine
to alter the PK profile of cocaine (e.g. increasing its metabolism, altering its distribution)
in order to prevent cocaine from interacting with its major targets in the brain (131). Tables
1-1 and 1-2 summarized the literatures reporting the results of preclinical studies and
clinical studies of immunotherapy-based agents and enzyme-based agents, respectively.
1.5.1. Vaccine and Anti-cocaine antibody
1.5.1.1.

Vaccine
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Vaccines for cocaine use disorder are immunogens consisting of a hapten
structurally similar to the cocaine conjugated to immunogenic carried protein. The
immunogens are formulated with adjuvants to increase immunogenicity. When immunized,
the conjugated immunogens lead to T cell-dependent B cell activation to generate
polyclonal anti-cocaine antibody with the ability to sequester cocaine and prevent its entry
to the brain (132).
The first anti-cocaine vaccine (IPC-1010 or TA-CD) evaluated in clinical trials
consisted of cocaine derivative (succinyl norcocaine) coupled to recombinant cholera toxin
B (rCTB). In preclinical studies, TA-CD was shown to be effective in inducing cocaine
specific antibodies and reducing cocaine intake in rats, with serum antibody concentration >
0.05-0.07 mg/ml (133, 134). In the phase I clinical trial, the vaccine was well tolerated and
produced specific antibodies in a dose-dependent manner (135, 136). In a phase II clinical
trial that involved 115 outpatients addicted to opioids and cocaine undergoing substitution
therapy with methadone, only 38% of the participants treated with TA-CD evoked antibody
titer levels (≥ 43 µg/ml) required to significantly reduce cocaine access to the brain and to
prevent its euphoric effects (137). In a human lab study, it has been demonstrated that
subjects with TA-CD-induced high antibody titers had significantly reduced subjective
ratings after smoking cocaine (138). However, in the phase III clinical trial involving 300
cocaine dependent subjects, the results did not confirm the efficacy found in previous study
in subjects with high antibody titer (≥ 43 µg/ml) based on retention and attaining abstinence
(139).
In order to deal with the insufficient immune responses in most subjects, vaccines
based on the specific adenoviral vectors were developed. One of the novel cocaine vaccine
(dAd5GNE), which is comprised GNE, a cocaine-like molecule that is linked to the capsid
protein of a disrupted serotype 5 adenovirus, has shown efficacy in antagonizing cocaine
addiction-related behaviors in rats (140) and reducing cocaine binding to dopamine
transporter (from 62% to 20%) in non-human primate (141). Currently, a phase I trial of
this vaccine is recruiting patients (NCT02455479).
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1.5.1.2.

Anti-cocaine monoclonal antibody

Despite active immunization using vaccine, another method of immunotherapy for
cocaine use disorder is passive immunization based on a monoclonal antibody (mAb)
prepared in the laboratory (142). One apparent benefit of mAb over vaccine is immediate
onset of action without a requirement of multiple immunization and weeks to months
waiting time before effective titers generated.
Passive immunization studies with murine anti-cocaine mAbs, including MO240
(143), GNC92H2 (144, 145), have been demonstrated to attenuate the toxic and behavioral
effects of cocaine. Later, a chimeric human/murine anti-cocaine, 2E2, was generated in
transgenic mice engineered to produce human sequence mAb (146). This mAb has been
demonstrated to change the in vivo distribution of cocaine in mice with a concomitant
dramatic decrease in brain cocaine concentrations (147) and increased the level of cocaine
required to reinstate cocaine self-administration (148). Beside regular anti-cocaine mAbs,
catalytic antibody with the capacity to bind and degrade cocaine, were also developed (149).
One catalytic antibody, known as mAb 15A10 (kcat = 2.3 min-1 and KM = 220 µM), has
been demonstrated to be able to protect the animals against seizures and death in a model
of cocaine overdose (150, 151), attenuate the cardiovascular impact of cocaine in mice
(152), and alter the reinforcing effects of cocaine in rats (150, 151).
However, there has been no mAb assessed in clinical trials for cocaine use disorder
so far.
1.5.2. Enzyme-based therapy
Compared to immunological approaches, enzyme-based therapy has an inherent
advantage. Each enzyme molecule can degrade multiple drug molecules, depending on the
catalytic parameters of the enzyme such as the turnover number (catalytic rate constant
kcat), which is remarkably different from the well-known stoichiometric binding of an
antibody with drug.
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1.5.2.1.

Bacterial cocaine esterase and mutants

Bacterial cocaine esterase (CocE) is isolated from a strain of Rhodococcus
bacterium, which grows in the soil surrounding the roots of the coca plant (153). It has
been characterized that it breaks down cocaine at benzoyl ester bond (kcat = 468 min-1, KM
= 0.64 μM), producing ecgonine methyl ester (EME) and benzoic acid (154). In addition,
native CocE hydrolyzes cocaine with an 800-fold improved catalytic efficiency compared
to wild-type human BChE (155).
However, native CocE has a very short half-life of 12.2 min in vivo due to its poor
stability at physiological temperature (37) (156). This drawback largely limits its potential
to be developed as a therapeutic agent. Based on rational computational approach, a new
CocE form with double mutations (RQ-CocE), T172R-G173Q, has been designed and
validated to display enhanced stability at 37 without compromising its catalytical
efficiency (kcat = 3204 min-1, KM = 17 μM) (157). RQ-CocE has been tested in cocaine selfadministration models in rats to show a dose-dependent effect on reinforcing responding
(158). In addition, its effects in amelioration of cocaine-induced cardiovascular effects has
been tested in rodents (159) and in rhesus monkeys (160).
A phase IIa trial (NCT01846481) conducted by Reckitt Benckiser Pharmaceuticals
Inc. has demonstrated that RBP-8000 (RQ-CocE) with dose of 100 mg or 200 mg was safe
and well-tolerated. It rapidly reduced cocaine level by 98% within 2 min and caused a
blunting of physiological effects of cocaine compared with placebo (161). The sponsor
concluded that all the evidences supported its use for the treatment of cocaine intoxication.
1.5.2.2.

Human Butyrylcholinesterase and mutants

In human, the dominant pathway for cocaine metabolism is BChE-catalyzed
hydrolysis at the benzoyl ester group (162). All the metabolites of this metabolic pathway
are considered as non-psychoactive. A lot of evidences based on animal studies or human
clinical use supported that BChE is devoid of toxic effects. The safety of human BChE was
evaluated in mice and guinea pigs (163, 164). They demonstrated that no sign of toxicity
was found as measured by general observation, serum chemistry, hematology, and
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histological tissue changes. Purified human plasma BChE has been used in clinical for
treatment of organophosphate (OP) pesticide poisoning, succinylcholine apnea, or
mivacurium apnea for more than 50 years. Based on case reported from 1953 to 2005,
BChE has been used to treat about 150 patients with one of such conditions (165). However,
no adverse events were reported (165). Therefore, hBChE is an optimal candidate enzyme
for designing cocaine hydrolases (CocHs).
Given that the catalytic activity of wild-type BChE against naturally occurring,
biologically active (-)-cocaine is very low (kcat = 4.1 min-1, KM = 4.5 μM) (166), studies
were carried out in our lab to identify CocHs (hBChE mutants) with high catalytic activity
against (-)-cocaine based on computational modeling and simulations of the enzymesubstrate binding and transition state. Several CocHs have been identified to have more
than 1000-fold improved catalytic activity (167-169) selectively against (-)-cocaine. The
kinetic parameters of wild-type BChE and selective CocHs for enzymatic hydrolysis of (-)cocaine and acetylcholine (ACh) summarized from literatures are displayed in Table 1-3.
A series of experiments have been done to characterize their in vitro enzymatic properties
(170-172) and in vivo effectiveness for cocaine detoxification (167, 173).
1.5.2.3.

Long-lasting CocHs

Besides the catalytic efficacy, the circulatory half-life of CocH is also a critical
factor for achieving desired therapeutic outcome. The original forms of high-activity
CocHs have half-lives around 7.3 hours in rats (173). By modifying amino-acid residues
to specifically increase the thermal stability of one of the therapeutically valuable CocHs,
its biological half-life has been extended to ~13 hours in rats (174). In order to further
extend the biological half-lives of CocHs and obtain prolonged therapeutic effects suitable
for long-term cocaine addiction treatment, most promising CocHs were fused with one of
stabilizing protein carriers, including human serum albumin (HSA), Fc domain of human
IgG (Fc), and their mutants designed by our laboratory. HSA or Fc fusion could prevent
CocH from intracellular degradation via neonatal Fc receptor (FcRn) mediated recycling
(175).
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Albu-CocH (Albu-CocH1 or TV-1380) is a chimeric protein by fusing wild-type
human serum albumin (HSA) to the C-terminal of early discovered BChE mutant (E14-3)
in our lab (168). Experiments have been carried out to confirm its effectiveness in
attenuating the reinforcing effects of cocaine in rats (176, 177) and squirrel monkeys (178).
It has been known that TV-1380 has a half-life of 8 hours in rats (IV) (179), 28 hours in
squirrel monkeys (IV) (178). Phase I and Phase II clinical trials of TV-1380 have been
completed by Teva Pharmaceutical Industries Ltd. In the phase I study, normal volunteers
received up to four weekly intramuscular doses of TV1380. It has shown that, at doses of
up to 300 mg, TV-1380 is safe and well-tolerated. The plasma half-life is determined to be
43-77 hours in health human subjects (IM) (180). In a small study with recreational users,
subjects were administered single doses of TV-1380 and challenged with an intravenous
dose of cocaine 1, 4, and 7 days later. The results showed that TV-1380 dramatically
reduced the Cmax and t1/2 of cocaine in a dose-dependent manner (181). In the recent Phase
II clinical trial, the ability of TV-1380 to safely and effectively increase abstinence in
treatment-seeking individuals with cocaine dependence was evaluated (182). With the
enzyme dose (150 mg or 300 mg) and injection regime (once per week) used in this clinical
trial, TV-1380 failed to meet the primary endpoint (abstinence) in the study. Obviously,
the half-life of 43-77 hours is not sufficiently long for each dose of TV-1380 to be effective
for an entire week. Nevertheless, there was a dose-related increase in the percentage of
negative urines during the last two months of treatment (182). The results suggested it
might be beneficial for abstinence maintenance if the plasma levels of TV-1380 could stay
higher during the study by higher doses or more frequent administration (e.g. twice a week).
However, this would not be feasible due to the consideration of costs and acceptable
administration frequency. Based on a survey of treatment providers before the clinical
study, it is not acceptable if one injection product requires administration more than once
weekly (182). Overall, the current results positively to justify the development of an
enzyme form with both higher catalytic efficiency and longer biological half-life.
The fragment crystallizable (Fc) region of IgG is the important part to ensure the
long biological half-lives of antibodies. It can bind with the neonatal Fc receptor (FcRn) in
the acidic environment of the endosome to avoid lysosomal degradation (183). When it is
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transported to the cell surface and exposed to a neutral pH, IgG is released back in to the
main blood stream. The development of carrier protein technology enabled the usage of
the Fc region of human IgG to prolong the biological half-lives of other therapeutic proteins,
leading to fusion proteins with average biological half-lives up to 17 days (184, 185). In
our laboratory, this strategy has been recruited to design a long-acting CocH form that has
both the long biological half-life of an antibody and the high catalytic activity of a CocH
against (-)-cocaine.
The first published Fc-fused CocH form is CocH3-Fc (186), in which the C
terminus of CocH3 was fused with the N terminus of the hinge region linked with Fc. As
shown in Table 1-3, CocH3 has a significantly higher catalytic efficiency against (-)cocaine than does CocH1 or TV-1380. It has been confirmed that the CocH3-Fc not only
has a high catalytic efficiency against cocaine but also, like an antibody, has a considerably
longer biological half-life (e.g., ∼107 h in rats). A single dose of CocH-Fc was able to
accelerate cocaine metabolism in rats even after 20 days and thus block cocaine-induced
hyperactivity and toxicity for a long period of time. Based on the preclinical and clinical
performance of TV-1380, the CocH3-Fc was proposed to allow dosing once every 2–4
weeks, or longer, for treatment of cocaine addiction in humans.
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Table 1-1. Preclinical and clinical studies of major immunotherapy for cocaine use disorder
Biologic

Description

Preclinical study (specie/Reference)
Toxicity

Vaccine

TA-CD

dAd5GNE
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Antibody

MO240
GNC92H2

 Lethality
 Convulsion/seizures
(Mice (145))

2E2
Catalytic
antibody

mAb 15A10

 Lethality
 Convulsion/seizures
(Rat (150))
 Cardiovascular
(Mice (152))

Clinical study

Addiction-related behavior

Company/Sponsor

 Self-administration
(Rat (133, 134))

Celtic Pharmaceutical;
Baylor College of
Medicine

Phase/
NCT/Reference
I-IIa-IIb-III
NCT00969878
(137, 139)

New York State
Psychiatric Institute

NCT00965263
(138)

Weill Medical College
of Cornell University

I
NCT02455479

Behavioral sensitization
Reinstatement
(140)
 Self-administration
(Rat (134))
Reinstatement
(Rat (144))
Reinstatement
(Rat (148))
 Self-administration
(Rat (150, 151))

Table 1-2. Preclinical and clinical studies of major enzyme-based therapy for cocaine use disorder
Biologic
Description
Preclinical study (specie/Reference)

Mutants
of CocE

Double mutant
CocE
(RQ-CocE;
RBP-8000)

PEGylated
CCRQ-CocE
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Mutants
of BchE

AlbuBChE
(TV-1380,
Albu-CocH1)

CocH3
CocH3-Fc

Clinical study

Toxicity

Addiction-related behavior

Company/Sponsor

 Lethality
 Convulsion/seizures
(Rat (158, 187))
 Cardiovascular
(Rat (188);
Rhesus monkey (160))
 Lethality
(Rat (189))
 Cardiovascular
(Rhesus monkey (189) )
 Convulsion/seizure
(Rat (176))
 Blood pressure
(Rat (176))
 Cardiovascular
(Cynomolgus monkeys (191))

 Self-administration
(Rat (158))

Indivior Inc.

Phase/
NCT/Reference
I-II
NCT01846481
(161)

Teva
Pharmaceutical
Industries

I-II
NCT01887366
(181, 182, 192)

 Lethality
(173)

 Self-administration
(Rat (189, 190))
 Drug-discrimination
(Rat (190))
 Self-administration
(Rat (177); Squirrel monkeys
(178) )
 Drug-discrimination
(Squirrel monkeys (178))
 Reinstatement
(Rat (176); Squirrel monkeys
(178))
 Locomotor activity
(173)
 Locomotor activity
(186)

Table 1-3. Kinetic parameters of wild-type BChE and selective CocHs for enzymatic hydrolysis of (-)-cocaine and
acetylcholine (ACh)

Enzyme
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Wild-type BChE b
CocH1 (E14-3) c
A199S/S287G/A328W/Y332G
(168)
CocH2 c
A199S/F227A/S287G/A328W/E441D
(193)
CocH3 (E12-7) c
A199S/F227A/S287G/A328W/Y332G
(169)
E30-6 d
A199S/F227A/P285A/S287G/A328W/Y332G
(167)

kcat
(min-1)
4.1
3,060

(-)-cocaine
KM(µM)
kcat /KM
(M-1min-1)
4.5
9.1 × 105
3.1
9.9 × 108

RCEa
1
1080

kcat
(min-1)
61,200
5,320

ACh
KM(µM)
kcat /KM
(M-1min-1)
148
4.1 × 108
36
1.5 × 108

RCEa
1
0.37

1,730

1.1

1.6 × 109

1730

10,400

27

3.9 × 108

0.95

5,700

3.1

1.8 × 109

2020

11,900

37

3.2 × 108

0.78

14,600

3.65

4.0 × 109

4395

8,710

54.7

1.6 × 108

0.39

a

RCE refers to the relative catalytic efficiency (kcat/KM), i.e. the ratio of the kcat/KM value of the mutant to that of wild-type
BChE against the same substrate.
b

Data of wild-type BChE against (-)-cocaine is from the reference (166). Data of wild-type BChE against ACh is from the
reference (176).
c

Date from the reference (172).

d

Data from the reference (167).

1.6.

Hypotheses and Specific aims
The long-term goal of our laboratory is to develop the enzyme-based

pharmacotherapies for cocaine overdose and cocaine use disorder. Based on the therapeutic
outcomes shown in phase II clinical trial of TV-1380 (Albu-CocH1), we believe the
second-generation fusion CocH, Fc-fused CocH, which has longer biological half-life and
higher catalytic efficacy, is desirable for further development for cocaine overdose and
cocaine use disorder treatment.
In order to identify and characterize most promising enzyme form for further
development, Fc-fused CocHs were screened by in vitro binding affinity assays first.
Enzyme forms that have improved binding affinity with FcRn at pH 6 were further studied
in rats to characterize the biological half-lives via two administration routes (IV and IM).
The overall hypotheses of this dissertation are (1) fusion CocHs will have improved
performance on cocaine detoxification; (2) a single dose, which is translatable to bedside,
of the Fc-fused CocH will be long-term effective to block or attenuate abuse related effects
of cocaine.
In chapter two, fusion CocH and its corresponding unfused enzyme were compared
based on their effectiveness in facilitating recovery form toxic effects of a lethal dose of
cocaine in rodent rescue model.
In chapter three, Albu-CocH1 (TV-1380) served as an example to investigate the
clinical potential of enzyme-based therapy for cocaine overdose treatment.
In chapter four, selected Fc-fused CocHs were accessed on their effectiveness and
duration in blocking physiological and subjective effects of cocaine in rats.
In chapter five, the most promising forms of Fc-fused CocHs were chosen to study
their effects in blocking and attenuating the reinforcing effects of cocaine using selfadministration model in rats.
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2.

Chapter Two

Compare the Potency of CocHs and Fusion CocHs in Rodent Rescue Models
2.1.

Enzyme-based treatment for cocaine overdose
The toxicity induced by cocaine in animals and humans is attributed to its multiple

physiological effects in central nervous system and cardiovascular system, among others
(11). Like other commonly abused substances, cocaine use leads to neurological
impairments due to its neurotoxic effects mediated by dopaminergic and glutamatergic
neurotransmitter systems (30, 34). In severe cases, the acute toxicity associated with
cocaine overdose could cause life-threatening events including seizures, cardiovascular
failure, or respiratory depression (11). Practical emergency treatment for cocaine
intoxication includes initial administration of a benzodiazepine anticonvulsant agent (e.g.
diazepam) and/or physical cooling, followed by interventions aimed to relieve the other
symptoms (194).
The inherent difficulties of antagonizing physiological effects of drugs in the
central nervous system have led to exploring protein-based pharmacokinetic approaches
using biologics like vaccines, monoclonal antibodies, and enzymes (195, 196). In principle,
among various pharmacokinetic approaches, a drug-metabolizing enzyme should be the
most efficient for drug overdose treatment (196-199). In particular, each enzyme molecule
can degrade multiple drug molecules, depending on the catalytic parameters of the enzyme
such as the turnover number (catalytic rate constant kcat), which is remarkably different
from the well-known stoichiometric binding of an antibody with drug. Based on our
structure-and-mechanism-based computational design, efficient and thermally stable
cocaine-metabolizing enzymes have been discovered and developed recently as potential
candidates of therapies for cocaine overdose and addiction (157, 168, 169, 174, 200, 201).
These

computationally

designed

enzymes,

which

are

mutants

of

human

butyrylcholinesterase (BChE) or bacterial cocaine esterase (CocE), can rapidly convert
cocaine to non-psychoactive metabolites: ecgonine methyl ester (EME) and benzoic acid.
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Previously, several enzyme forms have been tested in rodent models of cocaine
toxicity. A thermostable CocE with double mutants (RQ-CocE or RBP-8000) (157) could
reverse hypertension and bradycardia caused by 5.6 mg/kg (IV) cocaine, when
administered 1 min prior to cocaine injection. Similarly, administrations of RQ-CocE
following doses of cocaine that are sufficient to produce convulsions in rats (180 mg/kg;
IP) can completely reverse the neurological and cardiovascular effects in rats (187). AlbuCocH1 (Albu-CocH or TV-1380), a chimeric protein by fusing wild-type human serum
albumin to the C-terminal of the early discovered BChE mutant (E14-3), was shown to be
able to protect and rescue both male and female rats from a lethal dose of cocaine (176).
Importantly, in the rodent models, Albu-CocH1 treatment remained fully protective for 12
hr (176), but the bacterial enzyme lost its ability to protect in 30 min or less. This is
consistent with the observation in the clinical trial of RBP-8000 that a rebound of cocaine
concentration was seen at later time points when the plasma concentration of PBR-8000
had declined (161). This indicated that the half-life of the therapeutic protein also plays an
important role influencing its performance in the cocaine detoxification treatment.
Besides RQ-CocR and Albu-CocH1, several other CocHs with higher catalytic
efficiency and their corresponding fusion proteins with extended biological half-lives have
been designed and characterized in our lab. CocH3 is a BChE mutant has ~2,020-fold
improved catalytic efficiency against naturally occurring (-)-cocaine (169, 171, 173).
CocH3-HSA and CocH3-Fc were made by fusing CocH3 with human albumin protein
(HSA) or the Fc region of human IgG (202), respectively. They have the similar catalytic
efficiency as CocH3, but distinct PK profiles. E30-6 is the most efficient CocH among all
published BChE mutants, which has ~4000-fold improved catalytic efficiency against
naturally occurring (-)-cocaine (167). E20-7 is an unpublished BChE mutant, which has
similar catalytic efficiency as E30-6. E20-7-Fc was made by fusion E20-7 with the Fc
region of human IgG. Therefore, E20-7-Fc has both higher catalytic efficiency and longer
biological half-life compared to CocH3. The enzymatic parameters and biological half-life
of each enzyme form are listed in Table 2-1.
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In the studies described this chapter, we are aiming to compare fusion CocHs and
their corresponding unfused enzyme based on their effectiveness in facilitating recovery
from toxic effects of a lethal dose of cocaine in rodent rescue model.
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Table 2-1. Enzyme kinetic parametersa and biological half-lifeb of CocHs
Enzyme

kcat (min-1)

KM(µM)

kcat /KM

Half-life (hr)

(M-1min-1)

In rats

CocH3

5700

3.1

1.8 × 109

7.3

CocH3-Fc

5700

3.1

1.8 × 109

~ 110

CocH3-Albu

5700

3.1

1.8 × 109

8

E30-6

14600

3.65

4.0 × 109

7.3

E20-7

~14600

~3.65

~4.0 × 109

7.3

E20-7-Fc

~14600

~3.65

~4.0 × 109

~ 110

a

Enzyme kinetic parameters for enzymatic hydrolysis against naturally occurring (-)cocaine.
b
T1/2 of slow phase calculated from the two-phase exponential decay model.
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2.2.

Materials and methods

2.2.1. Materials
The enzymes used in this study were prepared using the methods described in our
previous study (202, 203). Briefly, all the proteins were expressed in stable CHO-S cells
(developed in our lab using a lentivirus-based method). The protein production was
performed in an agitated bioreactor BioFlo/CelliGen 115 (Eppendorf, Hauppauge, NY).
Unfused CocHs (CocH3, E30-6, and E20-7) were purified using ion-exchange
chromatography (Q Sepharose® Fast Flow) followed by affinity chromatography
(hydroxyapatite column). HSA fused protein (CocH3-HSA) was purified using AlbuPure
affinity chromatography. Fc fused proteins (CocH3-Fc, E30-6-Fc, and E20-7-Fc) were
purified using protein A affinity chromatography. The processes of protein purification
were performed on an ÄKTA Avant 150 system (GE Healthcare Life Sciences, Pittsburgh,
PA).
(−)-Cocaine was provided by the National Institute on Drug Abuse (NIDA) Drug
Supply Program (Bethesda, MD).
2.2.2. Animals
A total of 30 female Wistar rats (220–250 g) and 30 male NIH Swiss mice were
used in this study. They were ordered from Harlan (Harlan, Indianapolis, IN), and housed
initially as two rats or five mice per cage. All rodents were allowed ad libitum access to
food and water and maintained on a 12 h light/12 h dark cycle, with the lights on at 8:00
a.m. at a room temperature of 21–22 °C. The animal protocol was approved by the IACUC
(Institutional Animal Care and Use Committee) at the University of Kentucky.
2.2.3. Rescue experiment in mice.
Mice received IP injection of 100 mg/kg (~ LD50) cocaine. After convulsion onset,
mice were rapidly moved into a restrainer to facilitate IV injection through tail vein. Rescue
treatment (vehicle or enzyme) were required to introduce within 1 min after the convulsion
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onset. Then, mice were returned to the chambers or containers for observation. Time from
treatment injection to the occurrence of death, righting reflex, or walk (free movement with
four limbs) were recorded. All the mice survived after the experiment were housed in their
home cages for one-week follow-up observation.
2.2.4. Rescue experiment in rat.
Rats received IP injection of 100 mg/kg (~ LD100) cocaine. Rescue treatment
(vehicle or enzyme) was IV injected immediately after the obvious sign indicating the onset
of cocaine-induced convulsion through a temporary catheter placed in the tail vein before
cocaine administration. 200 µl (the dead volume of the catheter) of saline was administered
after the enzyme to complete the enzyme injection. It generally took around 20s to finish
this procedure. Then, rats were immediately returned to the chambers or containers for
observation. Time from treatment injection to the occurrence of death, righting reflex, or
normal walk (free movement with four limbs) were recorded.
2.2.5. Statistical analysis
Incidence of death is reported as overall percentage for each group. Time was
presented as mean  SD (min) in the tables. Time comparison among all treatments were
preformed using one-way ANOVA with individual comparison made by Turkey’s post hoc
test when appropriate. Time comparison involving only two groups was made by un-paired
t-test.
2.3.

Experiments and results

2.3.1. Mice study
In this experiment, we compared the effects four CocH forms when used as an agent
to rescue the cocaine intoxicated mouse and to facilitate their recovery. All the mice were
randomly assigned to five groups, receiving different recue intervention within 1 minute
after the start of cocaine-induced tonic-colonic activity (convulsion). The treatments were
vehicle, CocH3, CocH3-Albu, CocH3-Fc, and E20-7-Fc at a dose of 0.4 mg/kg. CocH3 at
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this dose was able to achieve 100% rescue rate in a preliminary pilot study. The time of
convulsion onset, the incidence of death, the time of occurrence of righting reflex and
voluntary walk, with various rescue treatment are shown in Table 2-2.
In mice, IP administration of 100 mg/kg cocaine rapidly evoked convulsion, a
seizure related behavior, with an incidence of 100% in each group. The time to convulsion
onset had no significant difference among five groups, determined by one-way ANOVA
(F (4, 25) = 0.521, p = 0.721). Without any effective intervention, half of mice (3/6) in
control group died within 10 minutes after cocaine injection. Half of them barely survived.
However, it took them around 20 minutes to complete righting reflex and more than half
hour to be able to move voluntarily. Although they were able to move, they showed signs
of profound motor weakness. Two of the three survivors were found dead in their home
cages one or two days after the experiment.
Rescue intervention with any one of the CocHs, at a dose of 0.4 mg/kg, increased
the survival rate from 50% to 100%. The effects for facilitating recovery, evaluated as the
time to occurrence of righting reflex or voluntary movement after treatment injection,
showed differences among groups (F (3, 20) = 9.585, p < 0.001 for the time to righting
reflex, F (3, 20) = 10.75, p < 0.001 for the time to voluntary move). Result of Tukey’s post
hoc test indicated mice treated with CocH3 took significantly longer time to show a
righting reflex and voluntary move than the other three groups (Table 2-2). Once they were
able to move, no sign of discomfort could be identified. All the mice behaved as normal as
untouched mice 2 hours after the experiment and no death was found during one-week
follow-up observation.
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Table 2-2. Rescue study with male mice

Number

Timea to

of mice

convulsion

Vehicle

6

2.52 ± 0.86

50

6.93 ± 2.11

19.60 ± 2.96

29.94 ± 7.17

CocH3 (0.4 mg/kg)

6

2.33 ± 0.50

0

N.A.

4.38 ± 1.90

6.16 ± 2.42

CocH3-Fc (0.4 mg/kg)

6

2.03 ± 0.41

0

N.A.

2.13 ± 0.67*

3.30 ± 0.84**

CocH3-HSA (0.4 mg/kg)

6

2.63 ± 0.76

0

N.A.

1.37 ± 0.83***

2.71 ± 0.77***

E20-7-Fc (0.4 mg/kg)

6

2.54 ± 1.27

0

N.A.

1.31 ± 0.52***

2.04 ± 0.45***

Treatment

% Death

Timea to

Timeb to

death

righting reflex

Timeb to walk
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Minutes (Mean  SD) from injection of cocaine to convulsion or death, for those mice that demonstrated these characteristics.
Minutes (Mean  SD) from injection of treatment to occurrence of righting reflex and movement, for those mice that demonstrated
these characteristics.
*p  .05, ** p  .01, *** p  .001 compared to CocH3 group using one-way analysis of variance (ANOVA) followed by the Tukey
post hoc tests.
N.A. = not applicable
a

b

2.3.2. Rat study
In this experiment, we studied the effects of CocHs when used as an agent to rescue
the cocaine intoxicated female rats and to facilitate their recovery. All female rats were
randomly assigned to five groups, receiving different rescue intervention within 1 minute
after the start of tonic-colonic activity caused by a lethal dose of cocaine. The treatments
were vehicle, 0.3 mg/kg E30-6, 0.8 mg/kg E30-6, 0.3 mg/kg E20-7, and 0.3 mg/kg E20-7Fc. The time of convulsion onset, the incidence of death, the time of occurrence of righting
reflex and voluntary walk with various rescue treatments are shown in Table 2-3.
In female rats, IP administration of 100 mg/kg cocaine results in an incidence of
convulsion of 100% in each group. The time to convulsion onset had no significant
difference among five groups, determined by one-way ANOVA (F (4, 25) = 1.220, p =
0.326). Without any effective intervention, in the control group, all rats died. The mean
time to death was 7.03 ± 2.83 min.
Rescue intervention with E30-6 at both doses decreased the rate of cocaine induced
death from 100% to 0%. Rats treated with the high dose (0.8 mg/kg) of enzyme took
significantly shorter time to show righting reflex and movement compared to the rats
rescued by low dose (0.3 mg/kg) of enzyme.
Rescue intervention with E20-7 and E20-7-Fc at the dose of 0.3 mg/kg also
decreased the rate of cocaine induced death from 100% to 0%. The time to occurrence of
righting reflex had no significant difference between these two groups, however, rats
treated with the E20-7-Fc took significantly shorter time to have movement compared to
the rats rescued by E20-7.
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Table 2-3. Rescue study with female rats
Treatment

Number

Timea to

(dose)

of rats

convulsion

Vehicle

6

4.04 ± 1.62

6

E30-6
(0.3 mg/kg)
E30-6
(0.8 mg/kg)
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E20-7
(0.3 mg/kg)
E20-7-Fc
(0.3 mg/kg)

Timeb to

Timeb to righting

death

reflex

100

7.03 ± 2.83

N.A.

N.A.

6.80 ± 5.05

0

N.A.

1.24 ± 0.47

2.33 ± 1.01

6

4.18 ± 1.18

0

N.A.

0.62 ± 0.27*

1.23 ± 0.26*

6

3.98 ± 1.47

0

N.A.

0.88 ± 0.79

2.57 ± 0.86

6

3.91 ± 2.53

0

N.A.

0.37 ± 0.20

1.09 ± 0.49##

% Death

Timeb to walk

Minutes (Mean  SD) from injection of cocaine to convulsion or death, for those mice that demonstrated these characteristics.
Minutes (Mean  SD) from injection of treatment to occurrence of righting reflex and movement, for those mice that demonstrated
these characteristics.
* p  .05 compared to E30-6 (0.3 mg/kg) group using un-paired t-test.
##
p  .01 compared to E20-7 (0.3 mg/kg) group using un-paired t-test.
a

b

2.4.

Discussion and conclusion
In the experiments presented in this chapter, we compared the effects of fusion

CocHs and unfused CocHs on their performance in acute cocaine detoxification using
rodent cocaine overdose model. In both rat and mouse rescue models, animals rescued by
a fusion CocH recovered significantly faster than the rats rescued by the corresponding
unfused enzyme form with the same dose.
In the mice rescue study, all the enzyme interventions at a dose of 0.4 mg/kg were
able to effectively rescue the mice in each group, but those mice rescued by fusion CocHs
(CocH3-Fc, CocH3-Albu, E20-7-Fc) had significantly shorter recovery time, indicating
better therapeutic outcomes. This effect is largely due to the improved pharmacokinetic
characteristics of fusion CocHs provided by the carrier protein (HSA or Fc region of human
IgG). We did not find differences between the groups treated with CocH3-Fc and CocH3HSA, indicating this effect is not completely correlated with the biological half-life of each
fusion CocH. The carrier protein not only prolonged the slow phase half-lives of fused
CocHs, but also slowed down the sudden enzyme loss in the circulation system due to
distribution or degradation within 10 min after enzyme administration. Interestingly,
despite the fact that E20-7-Fc has two-fold improved catalytic efficiency compared to that
of CocH3-Fc and CocH3-HSA, we did not find significant differences in both indicators
between fusion version of E20-7 and fusion versions of CocH3 (only p<0.05 for time to
walk E20-7-Fc vs. CocH3-Fc). This may due to the small sample size or a ceiling effect
caused by fusion CocHs at this dose. If they are compared under a lower dose, the catalytic
efficacy will be more likely to serve as an important parameter influencing the recovery
rate.
In the female rat study, the different recovery rates between groups treated with
E20-7 and E20-7-Fc confirmed the results of the mice study. In addition, the two groups
treated with different doses of E30-6 indicated the contribution of dose in the recovery rate.
The higher the dose was, the faster the animals recovered. This is consistent with the results
found using Albu-CocH1 (176). However, in their study, 1 out of 5 female rats died even
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after rescue with Albu-CocH1 at a dose of 3 mg/kg. In our study, all female rats survived
after rescue by 0.3 mg/kg and 0.8 mg/kg E30-6, indicating improved catalytic efficacy of
CocHs could effectively lower the enzyme dose needed for cocaine detoxification in
clinical treatment. Moreover, E20-7-Fc at dose of 0.3 mg/kg enabled rats to recover as
faster as rats treated with 0.8 mg/kg E30-6. Considering the fact that E30-6 and E20-7 have
similar catalytic efficiency, this further suggested that fusion CocHs will provide the
similar therapeutic outcome at a lower dose.
Overall, these data showed that fusion CocHs with improved pharmacokinetic
characteristics would exhibit better performance in cocaine detoxification treatment.
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3.

Chapter Three

Clinical Potential of an Enzyme-based Novel Therapy for
Cocaine Overdose Treatment
3.1.

Model the cocaine overdose treatment in a clinically relevant manner
Preclinical studies on Albu-CocH1 and other mutants of BChE or CocE for cocaine

toxicity treatment in mice or rats reported so far included the protection and rescue
experiments. In the protection experiment, the animals were pretreated intravenously (i.v.)
with an enzyme before intraperitoneal (i.p.) injection of a lethal dose of cocaine (e.g. 180
mg/kg, LD100) (157, 158, 169, 200, 204, 205). In the rescue experiment, the enzyme was
administered right after the onset of cocaine-induced convulsion (which usually occurred
within first three minutes after i.p. injection of a lethal dose of cocaine) (159, 199, 206). In
the Chapter two of this thesis, we also used the similar rodent model to compare the effects
of CocH3 and its corresponding long-lasting versions (CocH3-Albu, CocH3-Fc) in
facilitating the recovery of the subjects after challenged with a lethal dose of cocaine.
However, the timing of the interventions introduced in these animal models raised concerns
about the clinical irrelevance; it was regarded as “a difficult transition to the bedside” (207).
In fact, more than 40% of patients present to the emergency department with cocaine
toxicity more than 1 hour after cocaine use (207). The protection and rescue experiments
reported so far have no indication concerning whether the enzyme therapy will be effective
in these late presenters.
For an appropriate use of animal models with clinically relevant timing, one first
needs to understand the general features of pharmacokinetic (PK) profiles of cocaine in the
body. It should be noted that the elimination half-life of cocaine in the blood is dependent
on the dose used in the PK study (26, 208), because all endogenous cocaine-metabolizing
enzymes are saturated when cocaine concentration is sufficiently high in plasma. A
pharmacological dose (50 mg or ~1 mg/kg) of cocaine had an average elimination half-life
of ~93 min in humans, and significant blood cocaine concentrations were detected at 12
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hours after cocaine infusion (209). Significantly higher doses of cocaine under the overdose
conditions are expected to have longer elimination half-lives and physiological/toxic
effects for a much longer period of time in humans. With the dose-dependence of cocaine
elimination half-life in mind, it is not very difficult to understand why many patients
suffered acute myocardial infarction at an average of 18 hours after cocaine use (210).
Rats metabolize cocaine in the same pathways as humans, although rats can
eliminate cocaine more rapidly than humans. Thus, cocaine generally has a significantly
shorter elimination half-life in rats compared to humans. For example, 5 mg/kg cocaine
(administered i.v.) had an elimination half-life of only ~23 min and did not show significant
concentration of cocaine after 60 min following the cocaine administration according to
our previously reported study (203). So, a period of 30 min for cocaine detoxification in
rats might be corresponding to a few hours for cocaine detoxification in humans.
In the research (211) described in this chapter, we used animal behavior studies
combined with blood sample analyses, aiming to investigate whether the enzyme AlbuCocH1 can be effective in relieving the toxic effects of cocaine when administered at
different time points after cocaine intoxication. In addition, the effects of Albu-CocH1 in
each model was compared with that of diazepam.
3.2.

Materials and methods

3.2.1. Materials
The purified Albu-CocH1 protein was prepared in our previous study (202). Briefly,
the Albu-CocH1 protein was expressed in stable CHO-S cells (developed in our lab using
a lentivirus-based method) that can stably produce the Albu-CocH1 protein. The protein
production was performed in an agitated bioreactor BioFlo/CelliGen 115 (Eppendorf,
Hauppauge, NY). Albu-CocH1 in the culture medium was purified by using AlbuPure
affinity chromatography on an ÄKTA Avant 150 system (GE Healthcare Life Sciences,
Pittsburgh, PA). AlbuPure was ordered from ProMetic (Rockville, MD). The purified
protein was dialyzed in a storage buffer (50 mM HPEPS, 20% Sorbitol, 1 M Glycine, pH
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7.4) and stored at −80°C before the use. (−)-Cocaine was provided by the National Institute
on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD); and [3H](−)-Cocaine (50
Ci/mmol) was ordered from PerkinElmer (Waltham, Massachusetts). Diazepam (Valium®)
injectable was from Hospira (Lake Forest, IL). All other chemicals were purchased from
Thermo Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO).
3.2.2. Animals
A total of one hundred and thirty seven (137) male Sprague-Dawley rats (220–250
g) were ordered from Harlan (Harlan, Indianapolis, IN), and housed initially as one or two
rats per cage. All rats were allowed ad libitum access to food and water and maintained on
a 12 h light/12 h dark cycle, with the lights on at 8:00 a.m. at a room temperature of 21–22
C°. Experiments were performed in a same colony room in accordance with the Guide for
the Care and Use of Laboratory Animals as adopted and promulgated by the National
Institutes of Health. The animal protocol was approved by the IACUC (Institutional
Animal Care and Use Committee) at the University of Kentucky.
3.2.3. Determination of pharmacokinetic profiles of Albu-CocH1 in rats
Rats were injected with the purified Albu-CocH1 protein via tail vein (5 mg/kg).
Blood samples were taken from saphenous vein puncture using a needle. Approximately
40-75 µl blood was collected into a heparin-treated capillary tube at various time points
after enzyme administration. Collected blood samples were centrifuged for 15 min at a
speed of 5000 g to separate the plasma, which was kept at 4oC before analysis. A sensitive
radiometric assay using 100 μM (−)-cocaine was used to measure the enzyme
concentration in plasma (202).
3.2.4. Characterization of cocaine clearance in rats
Blood samples (40-75 μl) were collected from saphenous vein into a heparin-treated
capillary tube at various time-points after the (−)-cocaine administration, and mixed
immediately with 100 µl of 25 µM paraoxon (in 0.1% formic acid). Blood samples were
stored at −80 until analysis by using our previously developed LC-MS/MS method(212)
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for simultaneously detecting the concentrations of (−)-cocaine and metabolites in blood
samples.
3.2.5. Locomotor activity assay
Cocaine-induced hyperactivity was monitored by using a video-tracking system in
our lab. The locomotor activity tests were performed in high-density, non-porous plastic
chambers measuring 50 cm (L) × 50 cm (W) × 38 cm (H) in a light- and sound-attenuating
behavioral test enclosure (San Diego Instruments, San Diego, CA). Cumulative distance
traveled was recorded by ANY-maze video tracking system (San Diego Instruments, San
Diego, CA) to represent the locomotor activity. Before cocaine or saline administration,
rats were allowed to acclimate to the test chambers for 1 h. The distance traveled was
collected in 5-min bins. After cocaine or saline administration, rats were immediately
returned to the test chamber for activity monitoring for 6 hours with or without
administration of 5 mg/kg Albu-CocH1 or diazepam at 30 min or 60 min after the cocaine
administration.
3.2.6. Protection study in rats
Cocaine-induced acute toxicity was characterized in this study by the occurrence
of convulsion and/or death. Cocaine-induced convulsion was defined as loss of righting
posture for at least 5 seconds with the simultaneous presence of clonic limb movements
(213). Protection experiment was performed by pretreatment of rats with 5 mg/kg AlbuCocH1 (i.v.) or diazepam (i.p. or i.v.) 1 min (if i.v.) or 5 min (if i.p.) before administration
of 180 mg/kg cocaine (i.p.). Following the cocaine administration, rats were immediately
placed in containers for observation. The presence or absence of convulsion/death was
recorded for 6 hours following cocaine administration.
3.2.7. Rescue experiment in rats
Rats were treated with 60mg/kg (~ LD75), 180 mg/kg cocaine ( > LD100) (i.p.). 5
mg/kg CocH1-HSA (i.v.) or diazepam (i.p. or i.v.) were administered 30 min after cocaine
injection (for rats received 60 mg/kg cocaine) or within 1 min after the onset of cocaine49

induced convulsion (for rats received 180 mg/kg cocaine). Then, rats were immediately
returned to the chambers or containers for observation.
3.2.8. Statistical analysis
The Chi-squared contingency test was used to determine the overall significance of
the incidence of convulsions and deaths against control group in protection and rescue
experiments. The two-way repeated measures analysis of variance (ANOVA) was used to
determine the significance of treatment effect on the cocaine induced locomotor activity.
Cocaine PK data were analyzed by using two-way analysis of variance (ANOVA) method
and post hoc Dunnett’s test. All of the statistical analyses were carried out using the
SigmaPlot software (Systat Software, San Jose, CA).
3.3.

Experiments and results

3.3.1. Cocaine PK profile and cocaine-induced hyperactivity
As mentioned above, the elimination half-life of cocaine is dependent on the actual
dose. In this study, we first studied the PK profile of 60 mg/kg cocaine administered via
intraperitoneal (i.p.) injection. According to our PK data depicted in Figure 3-1 A, 60
mg/kg cocaine had an elimination half-life of ~56 min and still showed a significant
concentration of cocaine (~0.6 μM) at four hours after the cocaine injection.
A significant blood concentration of cocaine is associated with various
physiological/toxic effects. In rat models, it is convenient to observe cocaine-induced
hyperactivity, convulsion (a symptom of seizure), and death. We carried out locomotor
activity tests in rats using various i.p. doses of cocaine (10, 20, 40, 60, 100, and 180 mg/kg,
n = 8 per dose). As shown in Figure 3-2, changing the dose of cocaine from 10 to 60 mg/kg,
the duration of cocaine-induced hyperactivity became longer and longer, roughly ~1 hour
for 10 mg/kg, ~2 hours for 20 mg/kg, ~3 hours for 40 mg/kg, and ~4 hours for 60 mg/kg.
The ~4-hours hyperactivity (Figure 3-2 C) induced by 60 mg/kg cocaine is consistent with
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the observed significant blood cocaine concentrations within the four hours after the
cocaine administration.
3.3.2. Correlation between blood concentration and lethality of cocaine
In addition to the hyperactivity, 60 mg/kg cocaine induced convulsion in six out of
eight rats, and two rats died after convulsion (one at ~18 min and the other at ~24 min).
The average time for the onset of cocaine-induced convulsion was ~10.3 min after
administration. As shown in Figure 3-1 A, cocaine concentration in the blood reached a
peak of ~7 M (or ~7000 nM) at ~10 min after i.p. administration of 60 mg/kg cocaine.
Comparison of the animal behavior data in Figure 3-2 C with the cocaine PK data in Figure
3-1 A suggests that ~7 M is close to the threshold blood cocaine concentration leading to
convulsion in rats. When the blood cocaine concentration is around 7 M, the effects
caused by cocaine in the central nervous system could induce seizure, which manifests as
convulsions in the behavior of rats. This is also a critical period since persistent seizure is
most likely to cause sudden death. Since rats would not have free movement during
convulsion and/or after death, the observed average locomotor activity in Figure 3-2 C first
reached a peak at ~10 min and then dropped sharply due to the occurrence of convulsions
in several rats. Data from Figure 3-1 A also showed that the blood cocaine concentration
maintained above 5 M from 10 min to 60 min after cocaine administration. During this
period, the behavioral effects of cocaine varied over a large range in rats, which is the
reason for the big error bars in the figure when plotting the locomotion data. In some rats,
a blood concentration in this range mainly produced hyperactivity. However, in the other
rats, the blood concentration was high enough to maintain stereotyped behaviors, showing
as fast repetitive head and/or foreleg movement when remaining in the corner of the test
chamber (214). After an hour, the blood cocaine concentration dropped gradually to a level
below 5 M. Majority of the rats recovered from the restricted component of cocaine’s
effects and manifested hyperactivity as the behavioral effects of cocaine.
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Figure 3-1. Time-dependent blood concentrations of cocaine, cocaine metabolites, and
Albu-CocH1 in rats. (n=5 for each group) (A) – (C): Cocaine pharmacokinetics after i.p.
administration of 60 mg/kg cocaine without (A) and with i.v. administration of 5 mg/kg
Albu-CocH1 (B) or i.p. administration of 60 mg/kg cocaine (C) at t=30 min. Black arrows
indicate the time point when the intervention was introduced. (D) Cocaine
pharmacokinetics in protection experiment. (E) Cocaine pharmacokinetics in rescue
experiment (blood samples were taken only after the Albu-CocH1 administration). (F)
Albu-CocH1 pharmacokinetics after i.v. administration of 5 mg/kg Albu-CocH1. p < 0.001
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and p < 0.05 indicates the significant differences in the pharmacokinetic data between the
treated group and the untreated group (panel A).
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Figure 3-2. Cocaine-induced locomotor activity in rats. For each group of rats (n=8),
rats were first allowed to acclimate to the test chambers for 60 min before i.p.
administration of cocaine or saline. Cocaine dose: (A) 180 mg/kg; (B) 100 mg/kg; (C) 60
mg/kg; (D) 40 mg/kg; (E) 20 mg/kg; (F) 10 mg/kg. Data are plotted as the mean ± s.e.m.
meters traveled in 5-min bin during 7-hour tests. With the lethal doses in (A) to (C), the
recording was terminated after the occurrence of death.
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3.3.3. Rescue effects of Albu-CocH1 and diazepam on the toxicity of a lethal dose (60
mg/kg, i.p.) of cocaine
Since the blood cocaine concentration reached the peak at ~30 min after i.p.
administration of 60 mg/kg cocaine (Figure 3-1 A), in this set of experiments, we wanted
to see whether administration of 5 mg/kg Albu-CocH1 or diazepam at 30 min after cocaine
administration can help to reverse the cocaine toxicity, as shown in Figure 3-3. As
mentioned above, most of rats had convulsion after i.p. administration of 60 mg/kg cocaine,
and about 25% rats died before 30 min after cocaine injection. Rescue procedures were
only performed on rats that had convulsion but were still alive at 30 mn or 60 min after
cocaine administration.
The enzyme dose of 5 mg/kg used in our experiments is comparable to human dose
of 300 mg per person, assuming that the body weight of an adult is around 60 kg. This dose
has been proven safe for humans in the clinical trials for Albu-CocH1 which has an
elimination half-life of ~8 hours in rats as shown in Figure 1F and an elimination half-life
of 43-77 hours in humans (197, 198). For the sake of comparison, diazepam was expected
to be administered intravenously (i.v.) as the same as the administration route for AlbuCocH1. However, in our pilot study, 5 mg/kg diazepam administered i.v. caused strong
sedative effects in control group (without cocaine administration) with all rats lost righting
reflex and muscle tone immediately after injection and lasted for at least one hour. In the
other group, rats received 5 mg/kg diazepam (i.p.) exhibited drowsiness with slow and deep
respiration within 3 min. In addition, i.p. injection of diazepam was more commonly used
in the other studies and has been approved to be able to prevent the cocaine-induced
convulsion in the rats (215).Therefore, we chose i.p. injection as the appropriate route to
administer diazepam in this experiment.
According to data depicted in Figure 3-3B, i.p. administration of 5 mg/kg diazepam
significantly attenuated cocaine-induced hyperactivity. This behavioral result is largely
attributed to the central inhibitory effects of diazepam, rather than acceleration of cocaine
metabolism. On the contrary, according to data shown in Figure 3-1 C, diazepam actually
slowed down elimination of cocaine and its metabolites (p = 0.049 for cocaine, p = 0.046
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for benzoylecgonine, and p < 0.001 for norcocaine, according to statistical analysis using
the two-way ANOVA). Due to the sedative effects of diazepam, rats generally had slower
heart and breathing rates than normal during consciousness. This led to changed speed of
hepatic blood flow, which could be the factor altering the clearance rate of cocaine in the
rats. In comparison, i.v. administration of 5 mg/kg Albu-CocH1 immediately and
completely eliminated cocaine-induced convulsion and hyperactivity (Figure 3-3 A),
which is consistent with the cocaine PK data depicted in Figure 3-1B showing that cocaine
was metabolized rapidly after the enzyme administration. In particular, blood cocaine
concentration dropped from ~8 M to ~0.06 M in 2 minutes after enzyme administration.
Overall, Albu-CocH1 was able to completely and rapidly remove cocaine from the
blood stream and relieve all of the physiological effects caused by cocaine. Therefore,
Albu-CocH1 was much more effective than diazepam in cocaine toxicity treatment, if
Albu-CocH1 or diazepam was given when the blood cocaine concentration reached the
peak at 30 min after the 60 mg/kg cocaine administration.
In order to further study the effective window for Albu-CocH1 intervention, we
tested the effects of 5 mg/kg Albu-CocH1 when Albu-CocH1 was administered (i.v.) at 60
min after the 60 mg/kg cocaine administration (Figure 3-3 C). Due to the individual
differences discussed above, the average behavioral effects induced by 60 mg/kg cocaine
(i.p.) in the first hour after administration differed from the control group. In fact, there
were more rats in this treatment group showing prolonged stereotyped behaviors in the first
hour after cocaine administration, resulting in relatively lower average locomotor activity
shown in the figure. After i.v. administration of Albu-CocH1 at 60 min, all behavioral
effects caused by cocaine, including elevated locomotor activity and stereotyped behaviors,
were eliminated.
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Figure 3-3. Effects of 5 mg/kg Albu-CocH1 and diazepam on cocaine-induced
locomotor activity and toxicity in rats. (A) – (C): Rats (n=8 per group) were allowed to
acclimate to the test chambers for 60 min before i.p. administration of saline or 60 mg/kg
cocaine. (A) 5 mg/kg Albu-CocH1 (i.v.) or (B) 5 mg/kg diazepam (i.p.) was administered
at t=30 min or (C) t=60 min (Albu-CocH1 only) after the cocaine administration. Vertical
red dashed lines indicate the time points when the interventions were introduced. Data are
plotted as the mean ± s.e.m. meters traveled in 5-min bin during 7-hour tests. (D)
Occurrence of convulsions and death in protection and rescue experiments. p < 0.001 (or
***)

indicates

the

significant

difference

in

the

cocaine-induced

hyperactivity/convulsion/lethality between the treated group and the corresponding
untreated group.
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3.3.4. Rescue effects of Albu-CocH1 and diazepam on the lethality of an extremely
high dose (100 or 180 mg/kg, i.p.) of cocaine
As shown in Figure 3-2 A, increasing the lethal dose of cocaine from 60 mg/kg to
100 mg/kg, all rats started convulsion at ~6.3 min and died at ~18.1 min. This indicated
that 100 mg/kg (i.p.) was LD100 for rats. Using 180 mg/kg cocaine, all rats had convulsion
onset at ~2.8 min and died at ~4.1 min. Apparently, the higher the lethal dose of cocaine,
the sooner the convulsion and death will occur. Hence, it would be a bigger challenge to
detoxify subjects administered with further higher doses of cocaine in time.
Although the dose of 60 mg/kg examined above has already been sufficiently toxic,
we would still like to further test the effectiveness of Albu-CocH1 and diazepam in
protection and rescue rats from an even higher dose (180 mg/kg, LD100) of cocaine.
As shown in Figure 3-1 D, pretreatment of rats with 5 mg/kg Albu-CocH1 (i.v.) 1
min before i.p. administration of 180 mg/kg cocaine was able to rapidly and completely
convert cocaine to EME, a physiologically inactive metabolite, once cocaine diffused into
the blood. Blood cocaine concentrations (as well as the concentrations of cocaine
metabolites including benzoylecgonine  the dominant metabolite shown in Figure 3-1 A
in the absence of Albu-CocH1) at all time-points of blood sampling were negligible
compared to the corresponding EME concentrations. As a result, in the presence of AlbuCocH1, 180 mg/kg cocaine did not induce convulsion or death in any rats tested, as shown
in Figure 3-3 C and Table 3-1. The enzyme fully protected all of the rats from the acute
toxicity of 180 mg/kg cocaine. For comparison, rats were injected with 5 mg/kg diazepam
(i.p. or i.v.) 5 min (if i.p.) or 1 min (if i.v.) before i.p. administration of 180 mg/kg cocaine.
Due to the anticonvulsant effects of diazepam, all rats (except one out of 14) did not show
convulsion, but all rats died at ~9-10 min (Figure 3-3 C and Table 3-1), later than the death
of the control rats at ~4.1 min after cocaine administration. In conclusion, under the
condition of 180 mg/kg cocaine, diazepam was only able to extend the time between the
cocaine administration and death, without improving the survival.
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In further rescue experiments, rats were given 180 mg/kg cocaine (i.p.) first, and
then given 5 mg/kg Albu-CocH1 (i.v.) or diazepam (i.p. or i.v.) within 1 min after the onset
of cocaine-induced convulsion. As shown in Figure 3-3 D and Table 3-1, diazepam did not
rescue any rat. In comparison, the enzyme successfully rescued all rats; all rats survived
and recovered (i.e. have righting posture and move normally) at ~4.2 ± 1.9 min after the
cocaine administration (or ~1 min after the enzyme administration). The rescue effects of
the enzyme are consistent with cocaine PK data depicted in Figure 3-1 E showing the time
course of blood cocaine concentration after the enzyme administration. As seen in Figure
3-1 E, immediately after the enzyme administration, cocaine in the blood was converted to
physiologically inactive metabolite EME, which explains why all rats can recover so
rapidly.
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Table 3-1. Effects of diazepam and Albu-CocH1 on cocaine (180 mg/kg, i.p.) induced
convulsion and lethality in rats.
Drugs used
Cocaine (180
mg/kg)
Cocaine (180
mg/kg) and
Diazepam
(5 mg/kg)
Cocaine (180
mg/kg) and
Albu-CocH1
(5 mg/kg)

Expt.
method
Controla

Number
of rats
10

Time after cocaine injection (min)
Convulsion
Death
Recoveryf
2.78 ± 1.03
4.07 ± 1.87
N.A.

10 (i.p.)

N.O.

9.10 ± 2.11

N.A.

4 (i.v.)

9.10 (one rat)

9.91 ± 5.55

N.A

10 (i.p.)

2.75 ± 1.95

4.13 ± 2.76

N.A.

4 (i.v.)

2.84 ± 1.91

4.14 ± 2.17

N.A.

Protectiond

10

N.O.

N.O.

N.A.

Rescuee

10

2.82 ± 1.92

N.O.

4.2 ± 1.91

Protection

b

Rescue

c

a

Control experiment was performed by administration of 180 mg/kg cocaine (i.p.).

b

Protection experiment was performed by pretreatment of rats with 5 mg/kg diazepam (i.p.

for 10 rats and i.v. for 4 rats) 5 min (if i.p.) or 1 min (if i.v.) before administration of 180
mg/kg cocaine (i.p.).
c

Rescue experiment was carried out by first administration of 180 mg/kg cocaine (i.p.).

Then, in 1 min after the onset of cocaine-induced convulsion, rats were given 5 mg/kg
diazepam (i.p. for 10 rats and i.v. for 4 rats).
d

Protection experiment was performed by pretreatment of rats with 5 mg/kg Albu-CocH1

(i.v.) 1 min before administration of 180 mg/kg cocaine (i.p.).
e

Rescue experiment was carried out by first administration of 180 mg/kg cocaine (i.p.).

Then, in 1 min after the onset of cocaine-induced convulsion, rats were given 5 mg/kg
Albu-CocH1 (i.v.).
f

The clock time (starting from the cocaine administration) when the rats were fully

recovered (occurrence of righting reflex and normal walk) from cocaine-induced
convulsion.
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3.4.

Discussion and Conclusion
Cumulative evidence from animal tests and clinical studies have consistently

demonstrated that the elimination half-life of cocaine is dependent on the cocaine dose in
both rats and humans. The higher the dose, the longer the elimination half-life of cocaine.
In addition, cocaine generally has a significantly shorter elimination half-life in rats
compared to that in humans. Based on the animal data, whenever Albu-CocH1 is given to
a living subject (no matter whether blood cocaine concentration has reached the peak or
not), the remaining cocaine in the body will be converted rapidly to physiologically
inactive EME and, thus, reverse the cocaine toxicity and help the subject to recover.
Further, according to our results, when the cocaine dose exceeds LD100, the time
window for rescue is relatively narrow. However, the lower the cocaine dose, the wider the
window for rescue. Our study has demonstrated that the rescue window associated with a
lethal dose of 60 mg/kg (i.p.) is very reasonable. It should be noted that, for human with a
60 kg body weight, 60 mg/kg would be equivalent to 3.6 g, much higher than commonly
used oral doses of 50-300 mg (216). The minimum lethal dose of cocaine was estimated to
be 1.2 g (http://drug.addictionblog.org/cocaine-overdose-how-much-amount-of-cocaineto-overdose/). With a significantly lower dose of cocaine, the time window for rescue will
be much wider, as in the cases of most cocaine overdose caused emergency department
visits. In addition, 30 min for rats may correspond to hours for humans because rats can
eliminate cocaine much more rapidly than humans.
It should also be noted that Albu-CocH1 is an investigational new drug (IND),
known as TV-1380 (197, 198, 217) approved by the FDA for clinical trials in cocaine
addiction treatment, rather than cocaine overdose treatment. The Phase I clinical trials have
consistently shown that Albu-CocH1 (or TV-1380) in a single dose or repeated doses of
300 mg is safe for use in humans.(197, 198) The Phase II clinical trial results “argue for
development of improved enzymes with greater catalytic activity”(217) in order to be
effective with the desirable once-weekly dosing schedule for cocaine addiction treatment.
The present study has demonstrated for the first time that Albu-CocH1 (or TV-1380) is
likely more appropriate for cocaine overdose treatment, and all of the animal data discussed
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above consistently indicate that Albu-CocH1 is much more effective than diazepam in
cocaine overdose treatment. As Albu-CocH1 has been proven safe for use in humans, one
may go ahead to conduct further clinical trials for the efficacy of CocH1 (or TV-1380) in
cocaine overdose treatment.
In general, all of the animal data discussed above suggest that the key to cocaine
toxicity treatment is to accelerate cocaine metabolism and rapidly convert cocaine to
physiologically inactive metabolite EME. Once cocaine is completely converted to EME,
the toxicity of cocaine will be reversed for the subjects. The general concept of enzyme
therapy approach may also be used to develop other drug-specific enzymes for effective
treatment of the toxicity of other abused substances.
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4.

Chapter Four

Effectiveness and Duration of Fc-Fused CocHs in Blocking and Attenuating
Psychomotor Stimulant Effects and Discriminative Stimulus Effects of Cocaine in
Male Rats
4.1.

The psychostimulant and discriminative stimulus effects of cocaine
As a potent inhibitor of monoamine reuptake transporters, administration of

cocaine induces series of physiological effects in both rodents and humans. Due to the role
of dopaminergic pathway in motor control, cocaine exhibits psychomotor stimulant effects
when injected into rodents. In addition, psychomotor sensitization occurs after repeated
cocaine treatment. This phenomenon is considered to play an important role in the
incentive-sensitization theory of addiction (218). Some studies suggested that the
neuroadaptations underlying these behavioral changes are related to the development of
cocaine addiction. Thus, cocaine-induced hyperactivity and development of behavioral
sensitization in rodents could be used as a behavioral endpoint to predict the effect of a
medicine on blocking or attenuating the physiological effects of cocaine. The
discriminative stimulus effects of cocaine are mediated by its interoceptive property
(subjective effects in human), which has been suggested to contribute to the relapse of
cocaine use in human. It has been well established to use drug discrimination techniques
to classify and characterize the discriminative stimulus effects of abuse drugs, which can
be viewed as analogues to the measurement of the subjective effects induced by drugs in
humans (92). Therefore, the discriminative stimulus effects of cocaine in rodents could also
be used as a behavioral endpoint to evaluate the effects of a medicine on blocking or
attenuating the relapse-related property of cocaine.
In a previous study, it has been shown that pretreatment of CocH3 could block the
hyperactivity induced by cocaine in mice (173). In addition, we have shown that one early
version of CocH3-Fc, CocH3-Fc(M3), could provide long-term blockade effect on cocaine
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induced hyperactivity in mice with a single dose and the duration of this protection was
dose dependent (186).
In order to further extend the biological half-life of Fc-fused CocH, more mutations
were induced to the carrier protein, Fc region, according to computational design and in
vitro studies. A new version of CocH3-Fc containing 6 mutations in the Fc region was
generated and selected based on the pharmacokinetic profile with IV and IM routes of
administration (unpublished data). Following that, fusion proteins E30-6-Fc and E20-7-Fc
were produced using the same Fc region.
In the studies demonstrated in this chapter, we used cocaine-induced hyperactivity
and discriminative stimulus effects as endpoints to characterize the effectiveness and
duration of long-lasting CocHs (CocH3-Fc, E30-6-Fc, and E20-7-Fc) in elimination or
attenuation of the physiological effects and subjective effects of cocaine.
4.2.

Materials and methods

4.2.1. Materials
The method to prepare the fusion protein (e.g. CocH3-Fc, E30-6-FC) used in this
study was previously reported in a study [118]. Briefly, the protein was expressed in stable
CHO-S cells (developed in our lab using a lentivirus-based method) that can stably produce
the fusion protein. The protein production was performed in an agitated bioreactor
BioFlo/CelliGen 115 (Eppendorf, Hauppauge, NY). Fc fusion protein in the culture
medium was purified by using protein A affinity chromatography, which was performed
on an ÄKTA avant 150 system (GE Healthcare Life Sciences). The purified protein was
dialyzed in a storage buffer (50 mM HPEPS, 20% Sorbitol, 1 M Glycine, pH 7.4) and
stored at −80°C before the use.
(−)-Cocaine was provided by the National Institute on Drug Abuse (NIDA) Drug
Supply Program (Bethesda, MD); and [3H](−)-Cocaine (50 Ci/mmol) was ordered from
PerkinElmer (Waltham, Massachusetts). (+/-)-Methamphetamine was purchased from
Sigma-Aldrich (St. Louis, MO).
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4.2.2. Animals
Seventy-two male Sprague-Dawley rats (220–250 g) were used in the experiments
described in this chapter. They were ordered from Harlan (Harlan, Indianapolis, IN), and
housed initially as two rats per cage. All rats were allowed ad libitum access to food and
water and maintained on a 12 h light/12 h dark cycle, with the lights on at 8:00 a.m. at a
room temperature of 21–22 °C. The animal protocol was approved by the IACUC
(Institutional Animal Care and Use Committee) at the University of Kentucky.
4.2.3. Determination of pharmacokinetic profiles of fusion CocHs in rats
Rats were injected with the purified fusion CocH proteins (CocH3-Fc, E30-6-Fc,
E20-7-Fc) via tail vein. Approximately 40-75 µl blood was collected into a heparin-treated
capillary tube from saphenous vein at various time points after enzyme administration.
Collected blood samples were centrifuged for 15 min at a speed of 5000 g to separate the
plasma, which was kept at 4°C before analysis. A sensitive radiometric assay using 100
μM (−)-cocaine was used to measure the enzyme concentration in plasma (202).
4.2.4. Locomotor activity assay
Locomotor apparatus
The locomotor activity tests were performed in high-density, non-porous plastic
chambers measuring 50 cm (L) × 50 cm (W) × 38 cm (H) (San Diego Instruments, San
Diego, CA). Cumulative distance traveled was recorded by ANY-maze video tracking
system (San Diego Instruments, San Diego, CA) to represent the locomotor activity.
Locomotor activity tests
One week after arriving in the animal facility, rats were allowed to stay in the test
chamber for 3 hours on 3 consecutive days to acclimate to the environment. On each test
day, each rat was placed in a square plastic chamber. After 1 hour, rats were injected (IP)
with saline or cocaine. Locomotion was recorded throughout the habitation period and 2
hours (1 hour for cocaine dose 10 mg/kg) after injection.
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4.2.5. Drug discrimination assay
Operant conditioning chamber
The experiment sessions were conducted in an operant conditioning chamber with
interior size of 30.5 cm (L) × 24.1 cm (W) × 21 cm (H) placed in a sound attenuating
cubicle (Med Associates, Fairfax, VT). Each chamber was equipped with two retractable
levers and a pellet dispenser which delivered 45 mg sucrose pellets (Bio-Serv, Frenchtown,
NJ) into a pellet cup between the two levers. In the chamber, a house light was mounted
on the wall facing the levers and pellet cup and a white light was located above each of the
levers.
Drug discrimination training
The rats are maintained at 80% of their free-feeding weights for the period of the
study. They were trained to respond for sucrose pellets under an FR1TO5 schedule with
only one lever available (left or right during alternating sessions) initially. The fixed ratio
was gradually increased to FR10TO5. Once rats consistently earned 10 pellets in 10 min
session, they were trained to discriminate 10.0 mg/kg (IP) cocaine from saline using a
double-alternation (SSCCSSCC…), two-lever discrimination procedure described in
standard protocol (92) and related literature (190). The position (right/left) of the cocaineappropriate lever was counterbalanced across rats.
During each training session, following cocaine or saline administration, rats were
placed into an operant chamber, illuminated by the house light, for a 15-min pretreatment
period. The start of the session was signaled by the EXT of the house light, insertion of the
levers, and the illumination of the white light above each of the levers. Completion of 10
presses (FR10) on the injection-appropriate lever resulted in sucrose pellet delivery
followed by a 5-second time-out (TO) during which the white lights above the levers were
extinguished. Responding on the alternate lever was recorded but had no scheduled
consequence. Sessions terminated after 10 pellets had earned or 10 min had elapsed,
whichever came first. When session ended, levers were retracted, white lights were
extinguished, and the house light was illuminated.
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Upon acquisition of the discrimination, defined as three consecutive sessions with
>80% injection-appropriate responding during the first ratio and entire session, the number
of components was gradually increased to 5, with each component identical to the initial
discrimination training session. Daily sessions comprising 1–5 components (randomized
across days), with each component preceded by the administration of either saline or 10.0
mg/kg IP cocaine. Training continued until rats were allocating at least 80% of their
responding on the injection appropriate during the first ratio of each component, as well as
for components as a whole.
Drug discrimination testing
Briefly, after acquisition of discrimination, a substitution study was conducted first,
in which the generalization gradients of cocaine (e.g. 0.32, 1.0, 3.2, and 10.0 mg/kg; IP)
and (+/-)-methamphetamine (METH) (e.g. 0.032, 0.1, 0.32, and 1.0 mg/kg: IP) after PBS
pretreatment was examined. Percentage of responses on the drug appropriate lever and the
rate of responding was recorded during the test of each dose. The ED50 (dose that produces
50% cocaine- appropriate responding) was calculated using non-linear regression analysis
to show the potency to produce cocaine-appropriate responding.
Following that, rats were subjects for pretreatment tests, in which a single dose of
1 mg/kg CocH3-Fc was administered. Ten times higher dose gradient of cocaine (e.g. 10.0,
32.0, 56.0, 100.0 mg/kg, IP) was evaluated on the same day and daily after CocH3-Fc
injection until rats allocate at least 80% of their responding on the cocaine-appropriate
lever following the training dose of cocaine (10.0 mg/kg, IP). Blood samples were collected
after each test session for enzyme concentration analysis.
4.2.6. Statistical analysis
All data reported in the texts and figures are mean ± s.e.m. The number of rats of
each group were indicated in the figure legend. Overall, within-group comparison was done
by one-way ANOVA with repeated tests over time. Between-group comparison was done
by two-way ANOVA (with repeated measurements over time) with pretreatment and time
as factors. Comparison on individual day (pretreatment group vs. control group) was
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conducted by t-test. Detailed statistical methods were addressed in the texts and the notes
under the figures when p value was reported. All statistical analysis were performed using
GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA).
4.3.

Experiments and Results

4.3.1. Experiment 1a, 1b, 1c, 1d. Locomotor activity and behavioral sensitization
induced by repeated cocaine IP injection
In this set of experiments, locomotor activity induced by repeated cocaine IP
injection at various doses (10 mg/kg, 20 mg/kg, and 40 mg/kg) was tested. On the last day
of acclimation (-1 day noted in the figures below), baseline of saline induced locomotor
activity of each rat was tested. All rats were randomly assigned to four groups. In order to
serve as the control groups in the following experiments, all rats were shortly restrained
and IV injected with vehicle (1 ml/kg) before the habitation period of locomotor test on
Day 0. Rats in Exp. 1a, 1b, and 1c were tested under the same injection paradigm with 10
mg/kg, 20 mg/kg and 40 mg/kg cocaine, respectively. During the repeated cocaine training
phase, rats received two times of cocaine injections on consecutive days (Day 0 and Day
1) followed by five times on every other day (Day 3, Day 5, Day 7, Day 9, and Day 11;
See Figure 4-1A). Locomotor activity was monitored for each cocaine injection. After the
training phase, cocaine (with group dose) induced locomotor activity was tested three times
with a week of withdrawal time between tests (Day 18, Day 25, and Day 32). Rats assigned
to Exp. 1d were injected with 20 mg/kg cocaine on Day 0 and every other day to Day 32
(See Figure 4-1B). Total distance moved per hour after cocaine injection on each training
day and test day are displayed in Figure 4-2.
In Exp. 1a, although the injection paradigm is slightly different from the commonly
used cocaine-sensitization procedure, which includes cocaine injections (10 mg/kg) on 8
consecutive days, the group revealed the similar results. The repeated cocaine treatment
produced locomotor sensitization as shown by a significant greater locomotor response to
the last injection (7th) of cocaine compared with the first (Figure 4-2A, one-way ANOVA).
This sensitized response lasted at least for 3 weeks indicated by the significant increased
69

locomotor response to the test cocaine injections on Day 18, Day 25, and Day 32
(individually compared with response to the first injection by paired t-test). The time course
of cocaine-induced locomotor activity on training days and test days are displayed in figure
4-3.
The two groups treated with 20 mg/kg cocaine (Exp. 1b and 1d) showed the similar
pattern with first 7 repeated cocaine injections (no effect of injection regime, F (1, 14) =
2.77, p = 0.118 by two-way ANOVA with repeated measures over time). The locomotor
response to cocaine injection increased at the beginning, reaching a peak at 3rd injection,
and then gradually decreased. Unlike the low dose group (Exp. 1a), the response induced
by the 7th injection was not significantly increased compared to the first injection (Figure
4-2B, C; within group one-way ANOVA with Dunnett’s post hoc). In Exp. 1b, among the
three test days, only the response to cocaine test on Day 18 was significantly greater than
the response to first cocaine exposure (paired t-test, p = 0.45). Responses on Day 18, Day
25, and Day 32 were significant decreased compared to the peak response induced by 3rd
cocaine injection (paired t-test). Comparing the later phase in Exp. 1b and 1d, cocaine
induced locomotor response on Day 18 and Day 32 were significantly lower in Exp. 1d
than in Exp. 1b, indicating a contribution of cocaine exposures to the suppression on
cocaine-induced locomotor activity. By review the video recording, we found the reduced
locomotor response was associated with increased rate and duration of stereotyped
behaviors (fast repetitive head and/or foreleg movement when remaining in the corner of
the test chamber) commonly inducing by cocaine injection at a higher acute dose (eg. 40
mg/kg, 60 mg/kg). The time course of cocaine-induced locomotor activity after each
cocaine injection is displayed in Figures 4-4 and 4-6, respectively.
In Exp1c, the 1st injection of 40 mg/kg cocaine evoked the highest locomotor
response during 1st hour after injection among all three doses. Then the response dropped
significantly with repeated injections. Cocaine with a dose at 40 mg/kg also led to
significantly increased locomotor activity at the 2nd hour after cocaine injection compared
to the saline baseline. The locomotor response during this period remained stable with
repeated injections. The responses to cocaine tests on Day 18, Day 25, and Day 32 were
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similar to the responses of last three injection in the training phase. In fact, 40 mg/kg
cocaine induced stereotyped behaviors in a subset of rats since the 1st injection. The time
course of locomotor activity showed two peaks with a trough at around 30 min after cocaine
injection (Figure 4-5). With repeated injections, the first peak became sharp and the time
between the two peaks was significantly prolonged. From the 5th injection (on Day 7),
almost all of the rats exhibited stereotyped behaviors from 10 min to 60 min after cocaine
injection, leading to a minimal lever distance moved during 1st hour after cocaine injection
(Figure 4-2D). This behavioral pattern was maintained during cocaine tests on Day 18, Day
25, and Day 32. The time course of cocaine-induced locomotor activity after each cocaine
injection are displayed in Figure 4-5.
Interestingly, in Exp. 1d, starting from 8th cocaine injection at a dose of 20 mg/kg,
the time course of locomotor activity showed this two-peak pattern as well (Figure 4-6).
This may indicate repeated cocaine exposures at a lower dose eventually lead to similar
sensitized stereotyped behaviors as those rapidly induced by higher dose of cocaine.
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Figure 4-1. Schedule of cocaine injection or enzyme injection. (A) and (B) present
schedules for cocaine injection used in experiments 1, 2, and 3 for cocaine-induced
locomotor activity tests. (C) and (D) present schedules for single enzyme injection (C) and
multiple enzyme injections.
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Figure 4-2. Total distance moved per hour after cocaine (saline) injection. Mean ±
SEM total distance moved in first hour after each cocaine injection in Exp. 1a (A), Exp. 1b
(B), Exp. 1d (C). Mean ± SEM total distance moved in the first hour (D) and the second
hour (E) in Exp. 1c. *: vs. 1st cocaine injection in the same group by one-way ANOVA
with Dunnett’s multiple comparisons test; $: vs. 1st cocaine injection in the same group by
paired t-test; &: vs. 3rd cocaine injection (peak response) in the same group by paired t-test;
#: vs. 3rd cocaine injection (peak response) in the same group by paired t-test; %: vs.
response on the same day in exp.1b by t-test. Applied to all the labels: *, p<0.05; **, p<0.01;
***, p<0.001
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Figure 4-3. Time course of locomotor activity induced by 10 mg/kg cocaine on training
days and test days in Exp. 1a. Data are displayed as mean distance (s.e.m.) moved in 5
min during 15 min before and 60 min after cocaine injection (t=0 min).
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Figure 4-4. Time course of locomotor activity induced by 20 mg/kg cocaine on training
days and test days in Exp. 1b. Data are displayed as mean distance (s.e.m.) moved in 5
min during 15 min before and 120 min after cocaine injection (t=0 min).
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Figure 4-5. Time course of locomotor activity induced by 40 mg/kg cocaine on training
days and test days Exp. 1c. Data are displayed as mean distance (s.e.m.) moved in 5 min
during 15 min before and 120 min after cocaine injection (t=0 min).
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Figure 4-6. Time course of locomotor activity induced by 20 mg/kg cocaine on every
other days in Exp. 1d. Data are displayed as mean distance (s.e.m.) moved in 5 min during
15 min before and 120 min after cocaine injection (t=0 min).
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4.3.2. Experiment 2. Long-term effects of CocH3-Fc on blocking psychostimulant
effects of cocaine – single IV injection and multiple IV injection
This experiment tested the effects of a single injection and multiples injections of
CocH3-Fc on blocking psychostimulant effects caused by repeated cocaine injections.
After saline baseline test, rats were randomly assigned to two groups. One group of rats
(CocH3-Fc-Single) received a single dose of 3 mg/kg CocH3-Fc (IV) pretreatment before
the habitation period of the locomotor test on Day 0 (Figure 4-1C). Another group of rats
(CocH3-Fc-Multiple) received the same enzyme pretreatment on Day 0 and a repeated dose
every 10 days (Figure 4-1D). Blood samples were withdrawn from rats in these two groups
every day to track the plasma enzyme concentration. The injection regime and dose of
cocaine is as same as used in Exp. 1b. Thus, Exp. 1b served as control group for this set of
experiments. Total distance moved per hour after cocaine injection on each training day
and test day and a plot of plasm enzyme concentration are shown in Figure 4-7. Time
course of locomotor activity of all groups on cocaine training days and test days are
displayed in Figure 4-8.
There were no significant group differences in spontaneous locomotor activity
emerged during the acclimation sessions nor saline-induced locomotor response (F (2, 21)
= 1.19, p = 0.323) before the cocaine training phase. Across the cocaine-training period,
during the first hour recording preceded by cocaine injection, there was a main effect of
treatment (F (2, 21) = 102.5, p < 0.0001), day (F (6, 126) = 10.72, p < 0.0001), and
treatment-by-day interaction (F (12, 126) = 7.395, p < 0.0001) (Figure 4-4A). Tukey’s post
hoc comparisons revealed no difference between CocH3-Fc-Single group and CocH3-FcMultiple group, but significant lower locomotor activity in both groups compared to the
control group (p < 0.0001). Apparently, CocH3-Fc pretreatment completed blocked 20
mg/kg cocaine-induced elevation in locomotor activity in both groups during the cocaine
training phase (Day 0 to Day 11) (Figure 4-5), when plasma enzyme concentration was
above 10 mg/L (Figure 4-4B). During tests on Day 18, Day 25, and Day 32, as the plasma
enzyme concentration was decreased, cocaine injection was able to gradually trigger
locomotor response in the CocH3-Fc-Single group (Figure 4-5). However, compared to the
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control group, the locomotor response was still significantly attenuated. This was attribute
to blockade of the development of behavioral sensitization during training phase and the
significant reduction of cocaine exposure time under the protection of residual enzyme
(Figure 4-7), rather than exhibition of stereotyped behaviors (confirmed with video). In the
CocH3-Fc-Multiple group, plasma enzyme concentration was maintained above 10 mg/L
during the month of the experiment. Cocaine injection was not able to trigger apparent
elevation on locomotor activity on all test days.
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Figure 4-7. Plasma enzyme concentration and cocaine-induced locomotor activity in
rats following CocH3-Fc single dose or multiple doses. (A) The mean (s.e.m.) distance
traveled for 1 hour immediately following cocaine or saline injection of each group. (B)
Daily plasma enzyme concentration in CocH3-Fc Single group and CocH3-Fc Multiple
group. ****: p<0.0001 control group vs. both enzyme treatment groups by postcomparison after two-way ANOVA (training phase) or one-way ANOVA (on each test
day); #: p< 0.05 vs. saline baseline of the same group by paired t-test.
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Figure 4-8. Time course of locomotor activity induced by cocaine on training days
and test days following CocH3-Fc single dose or multiple doses.
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4.3.3. Experiment 3a, 3b. Long-term effects of E30-6-Fc and E20-7-Fc on blocking
psychostimulant effects of cocaine
In this set of experiments, we studied the long-lasting effects of E30-6-Fc and 207-Fc on blocking and attenuating the psychostimulant effects caused by more intensively
repeated cocaine injections. After saline baseline test, rats were randomly assigned to two
groups (E30-6-Fc and E20-7-Fc). Each group of rats received a single dose of 3 mg/kg
E30-6-Fc (IV) or E20-7-Fc (IV) pretreatment before the habitation period of the locomotor
test on Day 0, respectively (Figure 4-1C). Blood samples were withdrawn from rats 1 hour
after enzyme injection and then daily after behavioral test to track the plasma enzyme
concentration. The injection regime and dose of cocaine is as same as used in Exp. 1d.
Thus, Exp. 1d served as control group for this set of experiments. Total distance moved in
first hour after each cocaine injection and a plot of plasm enzyme concentration are shown
in Figure 4-9. Time course of locomotor activity induced by cocaine on each day of E306-Fc group and E20-7-Fc group in Figures 4-10 and 4-11, respectively.
There were no significant group differences in spontaneous locomotor activity
emerged during the acclimation sessions nor saline-induced locomotor response (F (2, 21)
= 2.07, p = 0.151) before the cocaine training phase. Across all 17 cocaine tests in a month,
during the first hour recording preceded by cocaine injection, there was a main effect of
treatment (F (2, 21) = 98.7, p < 0.0001), day (F (16, 336) = 5.12, p < 0.0001), and treatmentby-day interaction (F (32, 336) = 13.34, p < 0.0001) (Figure 4-4A). Tukey’s post hoc
comparisons revealed no difference between E30-6-Fc group and E20-7-Fc group, but
significant lower locomotor activity in both groups compared to the control group (p <
0.0001). Mean plasma enzyme concentration during the time of the study in both E30-6Fc group and E20-7-Fc group are displayed in Figure 4-9 B. The pharmacokinetic profile
of each enzyme was similar as the data obtained from previous PK studies without cocaine
treatments (unpublished data).
Due to the locomotor response induced by cocaine were still significantly
attenuated on Day 32 with the presence of E30-6-Fc and E20-7-Fc, we conducted 4 more
tests to Day 40 in E30-6-Fc group and E20-7-Fc group. The locomotor responses induced
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by 21st cocaine injection on Day 40 in both groups with enzyme pretreatment were still
significantly lower than the initial response (1st cocaine injection) and the peak response
(3rd cocaine injection) in the control group (Figure 4-12 A and B).
A detailed analysis of distance moved in first 15 min of locomotor test is shown in
Figure 4-12 C-E. A single dose of E30-6-Fc was able to completely block psychostimulant
effects of cocaine (at a dose of 20 mg/kg) for 12 to 14 days (no significant increase in
locomotor activity in 0-5 min after cocaine injection compared to response to saline Figure
4-12 C). After that, enzyme could rapidly eliminate cocaine’s effects in 5 min and 10 min
for more than 20 days and 30 days, respectively (Figure 4-12 D and E).
The relation between cocaine-induced locomotor activity in 15 min and plasm
enzyme level was tested by correlation analysis. A negative correlation (R2 = 0.914) was
found between the behavioral response and enzyme level from Day 16 to Day 40 (Figure
4-12 F).
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Figure 4-9. Plasma enzyme concentration and cocaine-induced locomotor activity in
rats following a single dose of E30-6-Fc or E20-7-Fc. (A) The mean (s.e.m.) distance
traveled for 1 hour immediately following cocaine or saline injection of each group. (B)
Daily plasma enzyme concentration in E30-6 Single group and E20-7 Single group. # : p<
0.05 compared to saline baseline of the same group by one-way ANOVA with Dunnett’s
multiple comparisons test
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Figure 4-10. Time course of locomotor activity induced by cocaine on every other day
following E30-6-Fc single dose.
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Figure 4-11. Time course of locomotor activity induced by cocaine on every other day
following E20-7-Fc single dose.
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Figure 4-12. Locomotor activity in 15 min after each cocaine administration in rats
pretreated with a single dose of E30-6-Fc. (A)-(B): Locomotor activities (total distance
moved in an hour (A) and time course of movement (B)) induced by 1st & 3rd cocaine in
control group and by 21st cocaine on 40th day in enzyme treated group (30-6-Fc and 20-7Fc). (C)– (E): Scatter plot of distance moved in 0-5 min (C), 5-10 min (D), 10-15 min (E)
by individual rat after cocaine (or saline) injection on each test day. (ns: not significantly
higher compared to saline baseline using one-way ANOVA with Dunnett’s post hoc
comparison) (F) Regression slopes between plasma concentration of E-30-6-Fc (presented
87

as average of 8 rats on each day) and distance moved in first 15 min after cocaine injection
(presented as average of 8 rats on each day) from Day 16 to Day 40.
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4.3.4. Experiment 4. Pilot study: Long-term effects of CocH3-Fc on blocking
discriminative stimulus effects of cocaine.
In a pilot study, we evaluated the duration of CocH3-Fc’s effects on blocking the
discriminative stimulus effects of cocaine. A group of rats was trained to discriminate
cocaine from saline using a two-lever drug discrimination task.
As shown in Figure 4-13 A and B, cocaine produced dose-dependent increases in
the selection of the cocaine-associated level, with 99.86 ± 0.36% of presses occurring on
the cocaine-appropriate lever following the training dose of cocaine (10 mg/kg, IP).
Methamphetamine also produced similar dose-dependent increases in the selection of
cocaine-associated level in rat pre-trained to discriminate cocaine from saline, with a full
generalization to the discriminative stimulus effects of cocaine at 1 mg/kg.
Pretreatment with 1.0 mg/kg CocH3-Fc produced rightward shifts in the dose–
response curve for cocaine-induced increases in cocaine-appropriate responding (Figure 413 C and D). The ED50 of cocaine was significantly increased from 2.22 mg/kg (95% C.I.
= 1.40 - 3.30 mg/kg) to 44.59 mg/kg (95% C.I. = 32.72 - 66.77 mg/kg) after Fc-CocH3
treatment (24 hours). The discriminative effect induced by 10.0 mg/kg cocaine was
completely blocked by single dosing of Fc-CocH3 for 10 days (Figure 4-9 E). The minimal
plasma enzyme concentration to achieve this blockade effect was determined to be 0.99 ±
0.65 mg/L (mean ± S.D.).
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Figure 4-13. Effects of pretreatment with CocH3-Fc in rats trained to discriminate
cocaine from saline.
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4.4.

Discussion and conclusion

4.4.1. Effects of cocaine dose and injection regime on development of behavioral
sensitization.
In this chapter, we first studied the behavioral sensitization induced by repeated
cocaine injection at multiple-dose (10 mg/kg, 20 mg/kg, and 40 mg/kg, IP) conditions. In
consistent with literature, repeated IP administration of 10 mg/kg resulted in increase in
total distance moved captured by video tracking system, which met the general definition
of behavioral sensitization – progressively increased locomotion with repeated cocaine
exposure. However, for the groups with cocaine dose at 20 mg/kg and 40 mg/kg, the
patterns of behavioral change caused by repeated cocaine administration are distinct. In 20
mg/kg group, the locomotor response induced by cocaine initially increased and reached
peak with 3 to 4 injections, then, decreased gradually. In 40 mg/kg group, the locomotor
response decreased steeply starting from the second injection. Later, we found the
decreased locomotor response (horizontal movement) was due to increased time spending
on stereotyped behavior response. This observation is consistent with the assessments of
cocaine-induced locomotor activity after cocaine self-administration training. It has been
shown that extended access to cocaine fails to produce locomotor sensitization (90) but
does produce a sensitized stereotyped behavior response (91). As stated in the early
literature focusing on behavioral responses of psychostimulant (219-221), the behavioral
sensitization does not involve simply quantitative changes in a given behavior (e.g.
increased locomotion), but complex qualitative changes in patterns of behavior that vary
as a function of many factors, including dose, number of treatments, and so on (91). Our
results supported the statement that the typical pattern of behavioral sensitization induced
by repeated cocaine exposure involves a transition from behaviors dominated by locomotor
hyperactivity to behavior dominated by progressively more stereotyped activity (91). In
addition, the higher the cocaine dose is, the sooner the transition occurs, indicating a
contribution of cumulative cocaine exposure in this process. The comparison between Exp.
1b and Exp. 1d revealed the frequency and intensity of the cocaine exposure also played a
role in accelerating the transition.
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4.4.2. Long-lasting effects of Fc-fused CocHs on cocaine induced physiological and
subjective effects.
In this part, we first studied the long-lasting effects of a single dose and multiple
doses of CocH3-Fc using a standard animal model for behavioral sensitization, which was
used to evaluate the efficacy of CocH gene therapy and anti-cocaine vaccine combination
treatment (222) and cocaine vaccine (dAd5GNE) (223) in antagonizing cocaine-induced
locomotion in rats (as demonstrated in Exp. 2b). Based on the mechanism of action of
biologics developed using PK strategy, the dose of cocaine using in a model plays an
important role in determining the results. In order to induce more challenges to our enzyme,
we used cocaine dose at 20 mg/kg, rather than 10 mg/kg and 15 mg/kg used in two previous
studies. Even with the elevated cocaine dose, a single injection of CocH3-Fc (3 mg/kg)
was able to show significantly more effective in antagonizing cocaine-induced locomotion
and behavioral sensitization in rats compared to the other innervations. Rather than
attenuated locomotor responses exhibited during the cocaine training phase (development
of behavioral sensitization) in the other two studies, repeated administration of 20 mg/kg
cocaine failed to trigger any apparent increase in locomotion with the presence of CocH3Fc. In addition, the multiple-dose group demonstrated the possibility of eliminating
cocaine’s effects for a long term (e.g. a month, three months, six months…) by repeated
enzyme administration. However, we have not carried out further studies to produce
evidence from the cellular and molecular levels to show the long-term protective effects
provided by CocH3-Fc on the rodent nervous system.
In the next study, we introduced a more intensive repeated cocaine administration
regime at dose of 20 mg/kg (as demonstrated in Exp. 2d) to test the effectiveness and
duration of action with a single dose of E30-6-Fc and E20-7-Fc. These two enzyme forms
represent the top performing enzymes we had produced in terms of both in vitro catalytic
efficiency and in vivo biological half-life. Using this animal model, we were able to study
the relationship between behavioral responses of rats and concurrent plasma enzyme
concentration. As shown in the results section, E30-6-Fc and E20-7-Fc overall exhibited
equivalent efficacy during the one-month tests in blocking or attenuating the physiological
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effects induced by cocaine. Detailed analysis was performed using E30-6-Fc as an example.
It has been found that with a plasma enzyme concentration above 5.19 ± 0.52 mg/L, which
is up to 14 days after the single-dose enzyme administration, rats failed to show significant
elevated locomotor responses within 5 min (as well as within the 2-hour recording) after
20 mg/kg cocaine administration. From Day 16 to Day 22 after enzyme administration,
when the plasma enzyme concentration was within the range from 4.57 ± 0.60 mg/L to
3.13 ± 0.38 mg/L, physiological effects induced by cocaine, which lasts more than 80 min
in rats of control group, was eliminated within 5 min. Moreover, a negative correlation
found between the behavioral response within 15 min after cocaine injection and plasma
enzyme level during the later phase of the study (Day 16 to Day 40) confirmed the major
role of enzymatic activity on attenuation of behavioral responses.
Finally, in a pilot study using drug discrimination paradigm, it has been shown that
a single dose of 1 mg/kg CocH3-Fc was able to block the subjective effects induced by 10
mg/kg cocaine (IP) for up to 10 days. Although, the studies using higher CocH3-Fc dose
(3 mg/kg) was not included as part of this dissertation, the results revealed a dosedependent increase in the duration of blockade effects (unpublished data).

In conclusion, the results presented in this chapter strongly support the hypothesis
that the Fc fusion CocHs with significantly extended biological half-lives are able to
maintain long-term effectiveness in blocking or attenuating the psychological and
subjective effects of cocaine in vivo in a plasma enzyme concentration dependent manner.
Based on these results, CocH3-Fc and E30-6-Fc were picked to be assessed in intravenous
cocaine self-administration model for further evaluation.
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5.

Chapter Five

Effectiveness and Duration of Fc-fused CocHs in Blocking and Attenuating
Reinforcing Effects of Cocaine in Male and Female Rats
5.1.

The reinforcing effects of cocaine
Cocaine’s reinforcing stimulus effects, which are mediated by its action on the

mesolimbic dopaminergic pathway, are the key factors leading to cocaine’s abuse liability.
Intravenous self-administration (IVSA) using laboratory animal is a reliable model and
direct measurement of the reinforcing effects of drugs with substantial face validity and
predictive validity. It has been widely used as a gold standard in preclinical evaluation of
pharmacotherapies for the treatment of drug abuse. Generally, in preclinical evaluation, an
effective anti-cocaine treatment should be able to make the cocaine more like saline or a
lower dose by antagonizing its reinforcing properties.
It has been shown that enzyme Albu-CocH1 was able to block or attenuate the
reinforcing effects of cocaine in rats (176, 177) by accelerating the metabolism of cocaine
in the peripheral circulation system. However, the enzyme required daily injection (with
dose of 2 or 4 mg/kg) right before the test session to achieve the desired effects due to its
short half-life in the rats (~8 hour). The only reported long-lasting effects of a single
enzyme injection was produced by PEG-CCRQ CocE (190). However, the effects on
attenuating the reinforcing effects of cocaine only lasted for 3 days with a dose as high as
32 mg/kg, which is not possible to be translated to clinic use.
As shown in Chapter three, the Fc-fused CocHs newly developed in our lab were
able to block or attenuate the physiological effects of cocaine for at least 40 days with a
clinically translatable dose of 3 mg/kg. In the studies described in this chapter, two
promising Fc-fused CocHs (CocH3-Fc and E30-6-Fc) for further development were tested
on their effectiveness and duration in blocking and attenuating the reinforcing effects of
cocaine. The effects of E30-6-Fc were investigated in both male and female rats. In addition,
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the minimal plasma enzyme concentrations needed to completely block the reinforcing
effects induced by each cocaine unit doses (0.1, 0.32, and 1 mg/kg/inf.) were determined.
5.2.

Materials and methods

5.2.1. Materials
The method to prepared fusion protein (e.g. CocH3-Fc, E30-6-FC) used in this
study was previously reported in a study (202). Briefly, the protein was expressed in stable
CHO-S cells (developed in our lab using a lentivirus-based method) that can stably produce
the fusion protein. The protein production was performed in an agitated bioreactor
BioFlo/CelliGen 115 (Eppendorf, Hauppauge, NY). Fc fusion protein in the culture
medium was purified using protein A affinity chromatography, which was performed on
an ÄKTA avant 150 system (GE Healthcare Life Sciences). The purified protein was
dialyzed in a storage buffer (50 mM HPEPS, 20% Sorbitol, 1 M Glycine, pH 7.4) and
stored at −80°C before the use.
(−)-Cocaine was provided by the National Institute on Drug Abuse (NIDA) Drug
Supply Program (Bethesda, MD); and [3H](−)-Cocaine (50 Ci/mmol) was ordered from
PerkinElmer (Waltham, Massachusetts). (+/-)-Methamphetamine was purchased from
Sigma-Aldrich (St. Louis, MO).
5.2.2. Animals
Thirty-eight male and sixteen female Sprague-Dawley rats (300–350 g) were used
in the experiments described in this chapter. They were ordered from Harlan (Harlan,
Indianapolis, IN), and housed initially as two rats per cage. All rats were allowed ad libitum
access to food and water and maintained on a 12 h light/12 h dark cycle, with the lights on
at 8:00 a.m. at a room temperature of 21–22 °C. The animal protocol was approved by the
IACUC (Institutional Animal Care and Use Committee) at the University of Kentucky.
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5.2.3. Blood collection and measurement of plasma CocH concentration
At the time for treatment, rats were injected with the purified fusion CocH proteins
(CocH3-Fc or E30-6-Fc) via tail vein. Approximately 40-75 µl blood was collected into a
heparin-treated capillary tube from saphenous vein at 1 hour after enzyme administration
and daily after behavioral testing. Collected blood samples were centrifuged for 15 min at
a speed of 5000 g to separate the plasma, which was kept at 4°C before analysis. A sensitive
radiometric assay using 100 μM (−)-cocaine was used to measure the enzyme
concentration in plasma (202).
5.2.4. Surgery and apparatus for self-administration
Preparation and catheter implantation surgery
After one-week acclimation period in the new animal facility, rats were introduced
to the operant conditioning chambers for food reinforced lever press training for a 10 min
session daily. Once rats were able to earn 10 food pellets within 10 min under FR5 on 3
consecutive days, they were considered as well-trained and subjects to the catheter
implantation surgery.
All the rats passed the initial food training were implanted with polyurethane
catheters (C30PU-RFV1418, Instech Laboratories, PA) in the left femoral vein under
isoflurane anesthesia according to the method described in literature (224). The opposing
end of the catheters were passed under the skin to the rats’ back to emerge between the
scapular where they were attached to a rat VAH harness (VAH95AB, Instech Laboratories,
PA). Rats were allowed to recover for 6-7 days before all the experiment. Catheters were
flushed daily with 0.2 ml of heparinized saline (100 U/ml) before the start, and after the
completion of operant sessions.
Apparatus
All experiment sessions were conducted in an operant conditioning chamber with
interior size of 30.5 cm (L) × 24.1 cm (W) × 21 cm (H) placed in a sound attenuating
cubicle (Med Associates, VT). Each chamber was equipped with two retractable levers. In
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the chamber, a house light was mounted on the wall facing the levers and a white light was
located above each of the levers. A VTA spring tether (VAH95T, Instech Laboratories, PA)
was held above the chamber by a counterbalanced arm to connecting the syringe and
external port on the harness. The syringe pumps (PMH-100; Med Associates) were used to
deliver solutions under the control of Med-PC IV Software (SOF-735, Med Associates).
5.2.5. Intravenous self-administration training
5.2.5.1.

Acquisition and maintenance of cocaine self-administration under fixed-

ratio reinforcement
Rats were initially trained to press one lever (defined as the active level) for
injection of 0.4 mg/kg/inf. cocaine during a 2-hour session daily under a FR1TO5 schedule
of reinforcement with active lever counterbalanced across rats. At the beginning of the
session, the house light and fan were turned on. Illumination of the white light above the
active lever signaled drug availability. The press on the active lever resulted in unit cocaine
injection. During the 5-s time out (TO) period, the white light located on the active level
was turned off and responses were recorded but had no scheduled consequence. Once they
were able to acquire 20 infusions per session, the ratio requirement was gradually increased
(1, 3, 5) until rats were responding under an FR5TO5 schedule of reinforcement. Upon
stabilization of the cocaine intake under this schedule, rats were allowed to get access to
cocaine for at least 7 sessions for maintenance training.
5.2.5.2.

Multiple-dose cocaine self-administration

Upon stabilization of responding, daily 2-hour sessions were replaced by a multicomponent, 5-dose procedure. Under this procedure, increasing unit doses of cocaine (0,
0.032, 0.1, 0.32, and 1.0 mg/kg/inf.) were available during five sequential 30 min
components (modified from (190, 225)). Each component was initiated by the noncontingent delivery of the unit dose of the drug available for responding and separated by
a 2-min inter-component interval during which time the house light was turned off and the
levers were retracted. During the long-term multiple-dose testing after enzyme (or vehicle)
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administration, only 4 cocaine doses (0, 0.1, 0.32, and 1.0 mg/kg/inf.) were included in this
test.
5.2.5.3.

Cocaine self-administration under progressive-ratio reinforcement

After the dose–response function of cocaine self-administration was determined,
the rats were tested for cocaine self-administration under a progressive-ratio (PR) schedule.
Under the PR reinforcement, the response requirement began at one response per injection
and increased according to the following equation: responses/injection=(5 × e(injection number ×
0.2)

)−5 (103). When a rat failed to get the next infusion within 1 hr, the session ended.
5.2.5.4.

Methamphetamine self-administration under fixed-ratio reinforcement

For the last step during self-administration training, methamphetamine selfadministration at unit dose of 0.06 mg/kg/inf. under same fixed-ratio reinforcement
(FR5TO5) were tested on the cocaine dependent rats for at least 3 days. In order to match
the total session time and drug availability condition during multiple-cocaine selfadministration test in the following experiments, there was a 30 min extinction period
(equivalent to 0 mg/kg/inf. during multiple dose test) before the 90 min methamphetamine
self-administration session. The drug available session was initiated by the non-contingent
delivery of 0.06 mg/kg/inf. methamphetamine.
5.2.6. Statistical analysis
All data reported in the texts and figures are mean ± s.e.m. The number of rats of
each group was indicated in the figure legend. Between-group comparison was done by
two-way ANOVA (with repeated measurements over time) with pretreatment and time as
factors. Detailed statistical methods were addressed in the texts and the notes under the
figures when p value was reported. All statistical analyses were performed using GraphPad
Prism 7.0 (GraphPad Software, La Jolla, CA).
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5.3.

Experiments and results

5.3.1. Experimental 1: Establishment of a long-term testing model in rats
In this experiment, we first compared the sex differences in the intravenous selfadministration (IVSA) of cocaine and methamphetamine. Under a FR schedule of
reinforcement, we found that female rats took significantly more infusions of cocaine at a
unit dose of 0.4 mg/kg/inf. per session (120 min) compared to male rats in the maintenance
phase of cocaine IVSA (p < 0.0001 by t-test) (Figure 5-1 A). Whereas, there was no sex
difference on the methamphetamine intake at a unit dose of 0.06 mg/kg/inf. (Figure 5-1 B).
Two-way ANOVA analysis of cocaine dose response curves in both sexes revealed a
significant main effect of unit dose (F (4, 56) = 95.46, p < 0.001), a main effect of sex (F
(1, 14) = 89.12, p < 0.001), and a dose × sex interaction (F (4, 56) = 35.72, p < 0.001)
(Figure 5-1 C). Comparison of total cocaine intake during sessions with various unit doses
showed that female rats had a tendency to take more cocaine compared to male rats at the
low to medium unit dose range (0.032 mg/kg/inf. to 0.32 mg/kg/inf.), but similar amount
of cocaine as male rats at a higher unit dose (1 mg/kg/inf.) (Figure 5-1 D).
In order to study the sex differences in motivation for cocaine, male and female rats
were assessed under a PR schedule of reinforcement at two unit-doses (Figure 5-1 E, F,
and G). Two-way ANOVA revealed a significant main effect of unit dose (F (1, 14) =
66.92, p < 0.0001), a main effect of sex (F (1, 14) = 44.02, p < 0.0001), but no dose × sex
interaction (F (1, 14) = 0.027, p = 0.872). Bonferroni’s post hoc comparison showed that
both male and female rats earned significantly more infusions of cocaine at higher unit
dose (1 mg/kg/inf.) compared to lower unit dose (0.4 mg/kg/inf.). In addition, female rats
eared significantly more infusions of cocaine compared to male rats at both unit doses.

99

Figure 5-1. Comparison between male and female rats in cocaine and
methamphetamine self-administration. (A) and (B): Mean number (s.e.m.) of cocaine
(A) and methamphetamine (B) infusions under a FR schedule of reinforcement (****: p <
0.0001 by t-test). (C) and (D): Dose response curve of cocaine self-administration (C) and
corresponding cocaine intake per session (30 min) at each unit dose (D) (**: p < 0.01, ***:
p < 0.001, ****: p < 0.0001 by post hoc tests of two-way ANOVA). (E) – (G): Mean
number (s.e.m.) of cocaine earned (E), break point (F), and total active level presses (G)
under a PR schedule of reinforcement. (###: p < 0.001, ####: p < 0.0001 comparison
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between unit dose in the rats of the same sex; ****: p < 0.0001 comparison between sex
under same unit dose by post hoc tests of two-way ANOVA).
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In order to test the long-term effects of a single injection of enzyme on cocaine
IVSA and methamphetamine IVSA, we designed a 5-week testing schedule. This schedule
included weekly cocaine IVSA testing under a PR schedule, weekly methamphetamine
IVSA testing, and multiple-dose cocaine IVSA tests on the rest days (Figure 5-2 B).
Methamphetamine (0.06 mg/kg/inf.) IVSA under a FR schedule of reinforcement was
tested on Day 2, Day 9, Day 16, Day 23, and Day 30 after enzyme or vehicle injection.
Cocaine (1 mg/kg/inf.) IVSA under a PR schedule of reinforcement was tested on Day 5,
Day 12, Day 19, Day 26, and Day 33 after enzyme or vehicle injection. On the rest days
from Day 0 to Day 35 after enzyme or vehicle injection, multiple-dose cocaine (0.1, 0.32,
1 mg/kg/inf.) tests were conducted. The test on each day was preceded by a 30-min
extinction component. Each test was initiated by the non-contingent delivery of the unit
dose of the drug available for responding. At the minimal cost of time and materials, this
model enabled us to learn how a single-time enzyme treatment, depending on its PK profile,
changes the reinforcing efficacy of cocaine, pattern of cocaine intake at various doses, and
IVSA reinforced by methamphetamine.
We first tested this model in female and male rats treated with vehicle to study how
the rats behave under this long-term testing schedule. After IVSA training and baseline
acquisition showing in Figure 5-2 A, eight female rats and eight male rats received IV
injection of vehicle on Day 0 (denoted as Male Control and Female Control in contexts and
figures). Then, they were subjects of the 5-week testing schedule. As seen in Figures 5-3
and 5-4, both male and female rats maintained stable baseline-level drug intake under each
test condition. Therefore, the long-term testing schedule had no significant impact on
cocaine intake with each unit dose, cocaine infusions earned under FR schedule, and
methamphetamine intake in both male and female rats.
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Figure 5-2. Experimental design. (A) Timeline of the whole experiment, including
surgery, cocaine self-administration training, baseline acquisition, treatment, and posttreatment tests. (B) Detailed schedule of 5-week post-treatment self-administration tests.
(CMDT: cocaine multiple dose tests; METH: methamphetamine IVSA test; CPR: cocaine
progressive ratio test)
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Figure 5-3. Effects of long-term tests on multiple-dose cocaine self-administration
under a FR schedule of reinforcement in male and female rats. Mean number (s.e.m.)
of cocaine infusions per session (30 min) at unit dose of 0.1 mg/kg/inf. (A: male; B:
Female), 0.32 mg/kg/inf. (C: male; D: Female), and 1 mg/kg/inf. (E: male; F: Female)
before (Baseline) and daily (0 Day – 35 Day) after a single time vehicle treatment. (ns: no
effects of time by repeated measurements of one-way ANOVA)
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Figure 5-4. Effects of long-term tests on cocaine self-administration under a PR
schedule of reinforcement and methamphetamine self-administration under a FR
schedule of reinforcement in male and female rats.
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5.3.2. Experimental 2: Effects of a single dose of CocH3-Fc on cocaine and
methamphetamine IVSA in male rats
Six male rats were used to study the long-term effects of a single dose of CocH3Fc on cocaine and methamphetamine IVSA. Upon cocaine IVSA training and baseline
acquisition, rats were IV injected 3 mg/kg CocH3-Fc on Day 0 (denoted as Male CocH3Fc in the contexts and figures). Then, they were tested daily following the 5-week testing
schedule.
As shown in Figure 5-5, there were no group difference on the baseline-level
performance between Male Control and Male CocH3-Fc. However, the single-time
enzyme treatment significantly changed the number of drug infusions in the sessions
reinforced by cocaine under a FR schedule (Figure 5-6). At unit dose of 0.1 mg/kg/inf.,
mean number of cocaine infusions were significantly reduced in the Male CocH3-Fc group
for the period of all 5 weeks with infusion number close to 0 during first 3 weeks (Figure
5-6 A). At unit dose of 0.32 mg/kg/inf., mean number of cocaine infusions were
significantly changed in the Male CocH3-Fc group for 22 days with infusion number
decreased (close to 0) in the first 8 days and increased from Day 11 to Day 22 (Figure 5-6
B). At unit dose of 1 mg/kg/inf., mean number of cocaine infusions were significantly
changed in the Male CocH3-Fc group for 20 days with infusion number decreased (close
to 0) in the first 3 days and increased from Day 6 to Day 20 (Figure 5-6 C).
Male CocH3-Fc group took more cocaine in total compared to the Male Control
group during 3-4 weeks after enzyme treatment. However, it was noticed that Male CocH3Fc group stayed calm down after test sessions. They had no significant behavioral sign of
“high” when compared to the Male Control group.
With a PR schedule of reinforcement, rats in Male CocH3-Fc group earned
significantly less cocaine (1 mg/kg/inf.) infusions compared to Male Control in all tests
conducted (Figure 5-7 A-C). For IVSA reinforced by methamphetamine, two-way
ANOVA revealed no main effect of treatment (vehicle vs. CocH3-Fc) nor time (Figure 57 D).
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Figure 5-5. Baseline comparison between male control group and male CocH3-Fc
group. (A) Mean number (s.e.m.) of cocaine infusion (0.4 mg/kg/inf.) in last 7 sessions of
maintenance training under schedule of FR5TO5; (B) Cocaine dose response curve tested
in daily multiple-component session; (C) Mean number (s.e.m.) of cocaine infusion (1
mg/kg/inf.) earned under a PR schedule of reinforcement; (D) Mean number (s.e.m.) of
methamphetamine infusion (0.06 mg/kg/inf.) in the last methamphetamine test.
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Figure 5-6. Long-term effects of CocH3-Fc on multiple-dose cocaine selfadministration under a FR schedule of reinforcement in male rats. Mean number
(s.e.m.) of cocaine infusions per session (30 min) at unit dose of 0.1 mg/kg/inf. (A), 0.32
mg/kg/inf. (B), and 1 mg/kg/inf. (C) before (Baseline) and daily (Day 0 – Day 35) after a
single time treatment (vehicle or 3 mg/kg CocH3-Fc). (&: Significantly higher infusion
number vs. control group @: Significantly lower infusion number vs. control group)
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Figure 5-7. Long-term effects of CocH3-Fc on cocaine self-administration under a PR
schedule of reinforcement and methamphetamine self-administration under a FR
schedule of reinforcement in male rats. (A) – (C): Cocaine self-administration under a
PR schedule before (Baseline) and weekly after the single-dose treatment (vehicle or 3
mg/kg CocH3-Fc). Data are expressed as (A) Mean number (s.e.m.) of cocaine infusions
earned (**: p < 0.01; ***: p < 0.001; ***: p < 0.0001 vs. control group by post hoc tests of
two-way ANOVA), (B) Break point, defined as the final ratio completed before session
ceased, (C) Total active lever presses. (D) Methamphetamine self-administration under a
FR schedule before (Baseline) and weekly after the single-dose treatment.
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5.3.3. Experimental 3: Effects of a single dose of E30-6-Fc on cocaine and
methamphetamine IVSA in male and female rats
Eight male rats and eight female rats were used to study the long-term effects of a
single dose of E30-6-Fc on cocaine and methamphetamine IVSA in both sexes. Upon
cocaine IVSA training and baseline acquisition, rats were IV injected 3 mg/kg E30-6-Fc
on Day 0 (named as Male E30-6-Fc and Female E30-6-Fc in the contexts and figures).
Then, they were tested daily following the 5-week testing schedule.
For male rats, as shown in Figure 5-8, there were no group difference on the
baseline-level performance between Male Control and Male E30-6-Fc. However, the
single-time enzyme treatment significantly changed the number of drug infusions in the
sessions reinforced by cocaine under a FR schedule (Figure 5-9). At unit dose of 0.1
mg/kg/inf., the mean number of cocaine infusions was significantly reduced in the Male
E30-6-Fc group for the period of all 5 weeks with infusion number close to 0 during first
3 weeks (Figure 5-9 A). At unit dose of 0.32 mg/kg/inf., the mean number of cocaine
infusions was significantly changed in the Male E30-6-Fc group for 22 days with infusion
number decreased (close to 0) in the first 11 days and increased from Day 17 to Day 22
(Figure 5-9 B). At unit dose of 1 mg/kg/inf., the mean number of cocaine infusions was
significantly changed in the Male E30-6-Fc group for 24 days with infusion number
decreased (close to 0) in the first 4 days and increased from Day 10 to Day 24 (Figure 5-9
C).
Male E30-6-Fc group took more cocaine in total compared to the Male Control
group during 3-4 weeks after enzyme treatment. However, it was noticed that Male E306-Fc group stayed calm down after test sessions. They had no significant behavioral sign
of “high” when compared to the Male Control group.With a PR schedule of reinforcement,
rats in Male E30-6-Fc group earned significantly less cocaine (1 mg/kg/inf.) infusions
compared to Male Control in all tests conducted (Figure 5-10 A-C). For IVSA reinforced
by methamphetamine, two-way ANOVA revealed no main effect of treatment (vehicle vs.
E30-6-Fc) nor main effect time (Figure 5-10 D).
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Figure 5-8. Baseline comparison between male control group and male E30-6-Fc
group. (A) Mean number (s.e.m.) of cocaine infusion (0.4 mg/kg/inf.) in last 7 sessions of
maintenance training under schedule of FR5TO5; (B) Cocaine dose response curve tested
in a daily multiple-component session; (C) Mean number (s.e.m.) of cocaine infusion (1
mg/kg/inf.) earned under a PR schedule of reinforcement; (D) Mean number (s.e.m.) of
methamphetamine infusion (0.06 mg/kg/inf.) in the last mathamphatamine test.
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Figure 5-9. Long-term effects of E30-6-Fc on multiple-dose cocaine selfadministration under a FR schedule of reinforcement in male rats. Mean number
(s.e.m.) of cocaine infusions per session (30 min) at unit dose of 0.1 mg/kg/inf. (A), 0.32
mg/kg/inf. (B), and 1 mg/kg/inf. (C) before (Baseline) and daily (Day 0 – Day 35) after a
single time treatment (vehicle or 3 mg/kg CocH3-Fc). (&: Significantly higher infusion
number vs. control group @: Significantly lower infusion number vs. control group)
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Figure 5-10. Long-term effects of E30-6-Fc on cocaine self-administration under a PR
schedule of reinforcement and methamphetamine self-administration under a FR
schedule of reinforcement in male rats. (A) – (C): Cocaine self-administration under a
PR schedule before (Baseline) and weekly after the single-dose treatment (vehicle or 3
mg/kg E30-6-Fc). Data are expressed as (A) Mean number (s.e.m.) of cocaine infusions
earned (**: p < 0.01; ***: p < 0.001; *** : p < 0.0001 vs. control group by post hoc tests
of two-way ANOVA), (B) Break point, defined as the final ratio completed before session
ceased, (C) Total active lever presses. (D) Methamphetamine self-administration under a
FR schedule before (Baseline) and weekly after the single treatment.

113

For female rats, as shown in Figure 5-11, there were no group difference on the
baseline-level performance between Female Control and Female E30-6-Fc. However, the
single-time enzyme treatment significantly changed the number of drug infusions in the
sessions reinforced by cocaine under a FR schedule (Figure 5-12). At unit dose of 0.1
mg/kg/inf., mean number of cocaine infusions were significantly reduced in the Female
E30-6-Fc group for the period of all 5 weeks with infusion number close to 0 during first
3 weeks (Figure 5-12 A). At unit dose of 0.32 mg/kg/inf., mean number of cocaine
infusions were significantly changed in the Female E30-6-Fc group for 21 days with
infusion number decreased (close to 0) in the first 8 days and increased from Day 15 to
Day 21 (Figure 5-12 B). At unit dose of 1 mg/kg/inf., mean number of cocaine infusions
were significantly changed in the Female E30-6-Fc group for 25 days with infusion number
decreased (close to 0) in the first 4 days and increased from Day 7 to Day 25 (Figure 5-9
C).
Female E30-6-Fc group took more cocaine in total compared to the Female Control
group during 3-4 weeks after enzyme treatment. However, it was noticed that Female E306-Fc group stayed calm down after test sessions. They had no significant behavioral sign
of “high” when compared to the Female Control group.
With a PR schedule of reinforcement, rats in Female E30-6-Fc group earned
significantly less cocaine (1 mg/kg/inf.) infusions compared to Female Control in all tests
conducted (Figure 5-10A-C). For IVSA reinforced by methamphetamine, two-way
ANOVA revealed no main effect of treatment (vehicle vs. E30-6-Fc) nor main effect time
(Figure 5-10 D).
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Figure 5-11. Baseline comparison between female control group and female E30-6-Fc
group. (A) Mean number (s.e.m.) of cocaine infusion (0.4 mg/kg/inf.) in last 7 sessions of
maintenance training under schedule of FR5TO5; (B) Cocaine dose response curve tested
in daily multiple-component session; (C) Mean number (s.e.m.) of cocaine infusion (1
mg/kg/inf.) earned under a PR schedule of reinforcement; (D) Mean number (s.e.m.) of
methamphetamine infusion (0.06 mg/kg/inf.) in the last methamphetamine test.
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Figure 5-12. Long-term effects of E30-6-Fc on multiple-dose cocaine selfadministration under a FR schedule of reinforcement in female rats. Mean number
(s.e.m.) of cocaine infusions per session (30 min) at unit dose of 0.1 mg/kg/inf. (A), 0.32
mg/kg/inf. (B), and 1 mg/kg/inf. (C) before (Baseline) and daily (Day 0 – Day 35) after a
single time treatment (vehicle or 3 mg/kg CocH3-Fc). (&: Significantly higher infusion
number vs. control group @: Significantly lower infusion number vs. control group)
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Figure 5-13. Long-term effects of E30-6-Fc on cocaine self-administration under a PR
schedule of reinforcement and methamphetamine self-administration under a FR
schedule of reinforcement in female rats. (A) – (C): Cocaine self-administration under a
PR schedule before (Baseline) and weekly after the single-dose treatment (vehicle or 3
mg/kg E30-6-Fc). Data are expressed as (A) Mean number (s.e.m.) of cocaine infusions
earned (**: p < 0.01; ***: p < 0.001; *** : p < 0.0001 vs. control group by post hoc tests
of two-way ANOVA), (B) Break point, defined as the final ratio completed before session
ceased, (C) Total active lever presses. (D) Methamphetamine self-administration under a
FR schedule before (Baseline) and weekly after the single treatment.
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5.4.

Discussion and conclusion

5.4.1. Long-lasting effects of fusion CocHs on cocaine dose-response curve - cocaine
IVSA under a FR schedule of reinforcement
After a single dose of pretreatment (CocH3-Fc, E30-6-Fc, or vehicle), cocaine
dose-response curves were obtained under a multi-component FR5TO5 schedule of
reinforcement at a frequency of five times per week for 5 weeks. The cocaine doseresponse curves before (baseline) and on the selected days after the treatment in all enzyme
treatment groups are displayed in Figure 5-14. In general, a single dose (3 mg/kg) of Fcfused CocH is able to cause long-term rightward and downward shift on cocaine doseresponse curve in a time dependent manner. As the only essential variable changing with
time is the plasma enzyme concentration. So, the alternation on dose-response curve is
indeed plasma enzyme concentration dependent. This time-dependent change is an
evidence showing that the impact of Fc-fused CocH on cocaine IVSA is based on its
enzymatic activity.
Based on the baseline study, cocaine unit dose of 0.1 mg/kg/inf. is close to the
minimal cocaine unit dose to trigger (reinstate) and maintain continuous drug intake under
FR5 among male rats. Pretreatment with a single dose of Fc-fused CocH was able to block
the reinforcing effects of a priming injection of 0.1 mg/kg/inf. completely for 3 weeks. At
the last day of the study (Day 35), when the plasma enzyme concentration was below 0.2
mg/L, this unit dose failed to trigger and maintain continuous drug intake in all the rats. At
cocaine unit dose of 0.32 and 1 mg/kg/inf., a single dose of Fc-fused CocH completely
blocked the reinforcing effects of a priming injection of cocaine for various lengths of time,
depending on the catalytic efficiency of the CocH form and sex of the rat. The length of
blockade effect on reinforcing effects of cocaine (1 or 0.32 mg/kg/inf.) and threshold
plasma enzyme concentration are summarized in Table 5-1. After the break day, which is
defined as the day when individual rat completed more than 5 infusions (not included) in a
cluster when session started, majority of the rats were able to maintain continuous drug
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intake. However, the increased infusion number indicated they were reinforced at a lower
dose, as cocaine IVSA is featured by an inverted U-shaped dose-response curve.
An important argument against the therapeutic value of biologics treatment
developed according to a PK strategy is that their antagonist effects are surmountable,
especially when cocaine is administered via IV or SM. However, our results showed that
it is cocaine unit dose dependent. It is feasible to find the plasma enzyme concentration
with the ability to completely eliminate the reinforcing effects of cocaine based on the
common cocaine dose consumed by human. To our knowledge, the antagonist effect of Fcfused CocH (CocH3-Fc or E30-6-Fc) is the most difficult to overcome as compared to all
tested entities in this field, including anti-cocaine vaccine, anti-cocaine mAb, and
AlbuCocH1.
In addition, the methamphetamine intakes under the FR schedule of reinforcement
were not altered by the presence of enzyme. This result is another strong evidence to
support that the effects of Fc-fused CocHs on cocaine IVSA rely on enzymatic activity
rather than causing problem to the rats, like health issues or inability to perform the operant
task.
5.4.2. Long-lasting effects of fusion CocHs on reinforcing efficacy of cocaine –
cocaine IVSA under a PR schedule of reinforcement
In order to learn the effects of fusion CocHs on the reinforcing efficacy of cocaine,
as well as the motivation of rats to obtain cocaine, we recruited the assessment of cocaine
IVSA under a PR schedule of reinforcement in the current studies. It is evident that the
single-dose treatment was still effective to reduce the cocaine infusions (1 mg/kg/inf.)
earned under a PR schedule in both male and female rats 33 days after the pretreatment. It
strongly suggested that the reinforcing efficacy of cocaine and the motivation of rats to
obtain cocaine were attenuated for at least a month after the treatment.
By comparing the results of drug intake under a FR and a PR schedule of
reinforcement, it is interesting to notice that rats were able to compensate for the enzyme’s
effects by taking more infusions under a FR schedule, but not under a PR schedule. We
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consider the PR schedule of reinforcement more relevant to the situation in real life. In
order to compensate for the enzyme’s effects by taking more cocaine to achieve desired
level of “high”, one needs to pay more money to get the drug. The cost and risk associated
with this process increase progressively as the demand increases, which is not as easy as
pressing the level at FR5. In addition, the “wrong decision” for continuing drug intake is
always made under the intoxication of the previous drug exposure. If cocaine were
prevented from accumulation with the presence of enzyme, the time with higher risk or
motivation to continue drug seeking or drug taking would be shortened.
5.4.3. Comparison of effects of Fc-fused CocH in both sexes
As a preclinical evaluation, it is necessary to study the efficacy of the Fc-fused
CocHs in both sexes. We investigated the effectiveness and duration of action of E30-6-Fc
in both male and female rats.
In order to better interpret the data, we first investigated the sex differences in
baseline. We found (1) female rats took more cocaine infusions than male rats at lower
cocaine unit doses; (2) the minimal cocaine unit dose to trigger and maintain continuous
cocaine intake at FR5 in majority (~ 80%) of female is 0.032 mg/kg/inf., rather than 0.1
mg/kg/inf. for male rats; (3) female rats earned significantly more cocaine infusions than
male rats at both doses tested under the PR schedule of reinforcement. Most of these results
are consistent with the finding in other studies on sex differences in cocaine IVSA (226).
In general, female rats show more sensitivity to low cocaine unit dose and higher
motivation to obtain cocaine.
With the pretreatment of a single dose of E30-6-Fc, female rats showed similar
pattern of alternation on cocaine dose-response curve as male rats did (Figure 5-14).
However, the plasma enzyme concentration needed to block the reinforcing effects of
cocaine at the same unit dose in female rats are higher than that in male rats (Table 5-1).
We have shown in the cocaine overdose model that fusion CocHs share similar enzymatic
efficiency in vivo in male and female rats (227). Based on the finding from the baseline,
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this difference is due to female rats’ sensitivity to low unit dose and higher motivation for
drug seeking.
In conclusion, as demonstrated using cocaine intravenous self-administration
model, pretreatment with a single dose of Fc-fused CocH was able to block or attenuate
the reinforcing effects of cocaine for a long term. These results indicate Fc-fused CocHs
might be valuable for managing cocaine abuse and addiction.
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Table 5-1. Length of blockade effect on reinforcing effects of cocaine (1 or 0.32 mg/kg/inf.) and threshold plasma enzyme
concentration.
Cocaine Unit Dose
Enzyme

E30-6-Fc
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CocH3-Fc

Sex (number)

1 mg/kg/inf.

0.32 mg/kg/inf.

Daya

Concentrationb

Daya

Concentrationb

MALE (n=8)

6.38 ± 1.30

9.35 ± 2.21

13.00 ± 2.14

3.42 ± 1.49

FEMALE (n=8)

5.75 ± 0.46

12.56 ± 1.33

11.00 ± 2.69

6.51 ± 2.24

MALE (n=6)

3.83 ± 1.33

21.07 ± 3.30

9.33 ± 0.52

7.63 ± 1.56

Data are all presented as Mean ± s.e.m.
a

The length of blockade is defined the as the break day minus one. The break day is the day when individual rat completed more than

five infusions (not included) in a cluster when session started.
b

The plasma enzyme concentration on the day before the break day.
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Figure 5-14. Cocaine self-administration dose-response curves obtained under a multicomponent FR5 schedule of reinforcement
before, and on Day 1, Day 7, Day 14, Day 21, Day 28, and Day 35 after enzyme treatment in each group.

6.

Chapter Six: Overall Discussion

In this chapter, the results and conclusions of all experiments are summarized. In
addition, the limitations involved in the experimental design, animal models, and
equipment are discussed. At the last, some future perspectives for this project are stated.
6.1.

Summary of results
The major purpose of the research presented in this dissertation is to conduct

preclinical evaluations of Fc-fused CocHs as therapeutic agents for cocaine overdose and
cocaine use disorder treatment. Three promising fusion enzyme forms (CocH3-Fc, E30-6Fc, and E20-7-Fc) have been tested in one or multiple animal models, including rodent
rescue models and rodent models of cocaine addiction, for their effectiveness and duration
of action provided by a single dose. The summarized results are listed below:
Compared to their unfused enzyme forms, fusion CocHs had improved potency as
agents to rescue rodents and facilitate recovery from the toxic effects caused by a lethal
dose of cocaine.
Fusion CocH (e.g. AlbuCocH1) served as effective cocaine detoxification agents
by accelerating the metabolism of cocaine. Administration of fusion CocH was able to
reverse manifestations of toxic effects of cocaine immediately, no matter when the
intervention was given.
A single dose of Fc-fused CocH resulted in long-lasting blockage or attenuation in
cocaine-induced physiological and subjective effects in rats. The maximal length of
blockage and extend of attenuation were dependent on the plasma enzyme concentration.
As shown in cocaine intravenous self-administration model, a single dose (3 mg/kg)
of Fc-fused CocH (e.g. E30-6-Fc) effectively altered the dose-response curve of cocaine
and attenuated the reinforcing efficacy of cocaine for at least a month in both male and
female rats.
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Together, those results suggest that Fc-fused CocHs with higher catalytic efficiency
and longer biological half-life are promising candidates for clinical evaluation as
medications for cocaine overdose and cocaine use disorder.
6.2.

Future perspectives

6.2.1. Study the PK profiles and effects on cocaine IVSA of Fc fusion CocHs in nonhuman primate
In this dissertation, the preclinical evaluations of Fc-fused CocHs were only
conducted in rodents. To obtain more human-related results, it is interesting to study the
PK profiles and effectiveness of Fc-fused CocHs in blocking addiction-related effects of
cocaine in non-human primate. Previous studies using AlbuCocH1 has confirmed that
human-derived CocH could modify pharmacokinetic and abuse-related effects of cocaine
(178) in squirrel monkeys. Since the biological half-life of 5 mg/kg AlbuCocH1 in squirrel
monkey is only 56.6 hours, the antagonist effects lasted less than 5 days in the study. Based
on the estimated biological half-life of Fc-fused CocH, we would expect Fc-fused CocHs
to show a much longer duration of effectiveness as compared to AlbuCocH1 in non-human
primate.
6.2.2. Look for more biomarkers to extend clinical endpoints
Currently, the most common and primary efficacy endpoint in clinical trials for
substrate use disorder treatments is abstinence. This endpoint has been considered as
difficult to achieve (228), since a lot of medicines showing adequate efficacy in preclinical
animal models failed to meet this clinical endpoint. More and more researchers have raised
the point that developing and validating alternative outcomes could facilitate drug
development (228, 229). Based on the unique mechanism of action of enzyme-based
therapy, adequate enzyme activity could eliminate effects caused by cocaine. Therefore,
more research should be conducted to find biomarkers to show the long-term protective
effects associated with the presence of enzyme in the circulation system of cocaine addicts.
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The alternative clinical endpoints based on these biomarkers might be more meaningful
than “abstinence” in the evaluation of treatment efficacy of enzyme-based therapy.
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